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ABSTRACT
Improved routes to tetrabenzo[a,c,g,/]fluorene derivatives have been 
developed, allowing the synthesis of Na -17-tetrabenzo[a,c,g,i]fluorenyl- 
methoxycarbonyl (Tbfmoc) urethane derivatives of alanine, leucine, isoleucine, 
methionine and valine. The chloroformate and pentafluorophenyl carbonate of 17- 
tetrabenzo[a,c,g,i]fluorenylmethanol have been prepared and used to introduce the 
base-labile Tbfmoc group onto the Na -termini of resin-bound peptides.
The high affinity of the Tbfmoc group for porous graphitised carbon (PGC) 
has been exploited for the purification of a range of synthetic peptides (23-85 
residues). A comparison of various basic solvent sytems used to elute the purified 
peptide from PGC is presented. The hydrophobicity of the Tbfmoc group has been 
used to simplify the purification of a ubiquitin analogue, UbY59F (76 residues), by 
the enhanced retention of the Tbfmoc peptide on RP-HPLC.
A new synthesis of 2-hydroxydibenzocycloheptadien-5-one has been devised. 
This compound has been used to develop acid-labile linkers for the synthesis of 
peptide C-terminal alkyl amides and aza-glycine peptides, compatible with the 
FmocABu solid phase method. Alternative modes of attachment of the linker to 
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1.1 Solid Phase Peptide Synthesis (SPPS)
1.1.1 Introduction
The chemical synthesis of peptides relies upon the formation of an amide 
bond by the the reaction of the amine function of one amino acid with the activated 
carboxyl function of another. In order to prevent unwanted coupling between two 
molecules of the same species, the amine group of the activated amino acid and the 
carboxyl of the other are protected (Figure 1.1).
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Figure 1.1: General scheme for peptide synthesis 
Synthesis of a dipeptide
For longer peptides, the question arises as to the strategy of assembly of the
peptide. Three possible routes for the synthesis of an octapeptide, A-B-C-D-E-F-G- 
H, where A-H represent amino acids, are oudined in Figure 1.2.
A + B  C + D  E + F  G + H
t i l !
A-B+ C-D E-F + G-H
A + B G + H
A-B + C F + G-H
A-B-C-D + E-F-G-H A-B-C + D E + F-G-H
t
A-B-C-D-E-F-G-H A-B-C-D + E D + E-F-G-H
etc etc
(i) Fragment (ii) Stepwise elongation (iii) Stepwise elongation
condensation from N-terminus from C-terminus
Figure 1.2: Alternative strategies for 
the assembly of an octapeptide
In practise (ii) is discounted by racemisation considerations, leaving (i) fragment 
condensation and (iii) stepwise elongation from the C-terminus. Of these, fragment 
condensation would seem to be the preferred route when an average yield of 90% for 
each stage would give an overall yield of 73%, compared with 48% for stepwise 
assembly.
Fragment condensation has been employed with great success, allowing the 
synthesis of many biologically important peptides e.g. oxytocin1 (9 residues), the 
first peptide hormone to be chemically synthesised. Over the years, however, it 
became increasingly clear that a prodigious effort would be required to extend this 
method to the synthesis of longer, more complex peptides.
2
In 1962 Merrifield2 proposed the simple but ingenious idea of carrying out 
stepwise peptide synthesis from the C-terminus with the first amino acid covalently 
bound to an insoluble solid polystyrene support. This greatly simplified the task of 
peptide synthesis by:
(i) removing the need for conventional purification of intermediates (reagents 
and by products are removed by filtration);
(ii) minimising physical losses by retaining the resin-bound peptide in the 
same reaction vessel throughout the synthesis;
(iii) allowing excess reagents to be used to drive reactions to completion.
1.1.2 The Merrifield method of SPPS. Boc Methodology
In 1963 Merrifield3 reported the first solid phase synthesis of a peptide, a 
simple tetrapeptide, Leu-Ala-Gly-Val-OH, by the sequential condensation of Na - 
benzyloxycarbonyl amino acids. Although several truncated peptides were formed 
due to poor coupling reactions and/or incomplete deprotection of the N01-  
benzyloxycarbonyl protecting groups, the feasibility of the method had been clearly 
demonstrated.
A year later Merrifield4 proposed several modifications to the method, most 
notably the replacement of the Na -benzyloxycarbonyl protecting group by the t- 
butyloxycarbonyl (Boc) group. In this method (Figure 1.3), the caesium salt of the 
first Boc-protected amino acid is anchored to chloromethylated polystyrene resin by 
the formation of a benzyl ester. The N ^B o c  group is removed with TFA and the 
resulting TFA salt neutralised. The liberated amino group is then coupled to an 
amino acid using dicyclohexycarbodiimide (DCC) as an activating agent. These 
steps are repeated until the desired peptide has been assembled when it can be 
liberated from the resin, with concomittant removal of benzyl-based side chain 
protection, upon treatment with anhydrous HF.
3
Using this method, Merrifield was able to singlehandedly synthesise a 
nonapeptide, bradykinin, in highly purified form, a remarkable achievement at this 
time and a feat that would have taken a team of workers several weeks using 
classical solution phase techniques.
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Figure 1.3: Merrifield method of SPPS
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Merrifield’s contribution to peptide chemistry was subsequently recognised by the 
award of the Nobel prize in 19845.
Over the years, numerous refinements to the Boc method have been 
proposed. For instance, the peptide-resin benzyl ester linkage (Figure 1.3) has been 
shown to be partially cleaved by TFA, ca. 1-2% per cycle, as the synthesis proceeds, 
which can result in serious losses during longer syntheses. For this reason the more 
acid-stable PAM resin (1) has come into use6, where bleeding of the peptide from 
the resin is much reduced.
(1) PAM resin
Tam and co-workers7 have suggested a low-high HF cleavage procedure, 
whereby initially a low concentration of HF in a large amount of scavenger, such as 
DMS, is used. Under these conditions the cleavage mechanism changes from SN1 to 
SN2 (Figure 1.4). This has proved successful in suppressing alkylation of tyrosine by 
benzyl and t-butyl cations, succinimide formation in Asp-Gly sequences and 
acylation of scavenger molecules by glutamyl side chains. The low HF procedure is 
then followed by a standard HF cleavage to remove the more resistant protecting 
groups e.g. Arg(Tos) and Arg(NC>2).
Yajima8 has suggested TFMSA as an alternative to HF. TFMSA, although 
still highly corrosive, may be used with standard laboratory glassware, however it 
will not deprotect Arg(Tos) or Arg(NC>2).
5
HI
Figure 1.4: High (SN1) and low (SN2)
HF cleavage mechanism
1.1.3 Base-labile Na protecting groups. The Fmoc method of SPPS
The search for ever milder conditions for peptide synthesis prompted the 
introduction of the 9-fluorenylmethoxycarbonyl (Fmoc) group for Na  amino 
protection9.
The Fmoc group is base-labile by virtue of the acidic proton at the 9-position, 
allowing the group to be expelled by a (3-elimination mechanism on treatment with 
base (Figure 1.5). A variety of bases have been employed but secondary amines (e.g 
20% piperidine in DMF) are most commonly used.
Piperidine forms a stable adduct (15) with the liberated dibenzofulvene (14)9 
and the formation of this adduct can be detected by its UV absorbance at 300 nm. 
This has formed the basis of a UV monitoring method for automated SPPS1(*.
The base-lability of the Fmoc group combined with acid-labile side chain 
protection offers a truly orthogonal approach to peptide synthesis but although the 
Fmoc group was introduced by Carpino in 1972, it wasn't until almost a decade later 
that its potential in SPPS began to be realised, when Atherton and Sheppard adopted 
the Fmoc group for peptide synthesis on polyamide supports*1-13.
6
RNH-C = 0   ** RNH2
OH
Figure 1.5: Fmoc deprotection with piperidine
Following the success of the Fmoc group, other base-labile Na -protecting 
groups have since been suggested. These include the ¿ns-nitrophenylethoxyarbonyl 
(Bnpeoc) 14’15 (16) and dinitrophenylethoxycarbonyl16 (17) groups but none have yet 
come into routine use.
(16) Bnpeoc (17)
1.1.4 Fmoc methodology. Side chain protection
A base-labile Na -protecting group allows more acid labile side chain 
protection and t-butyl based groups (Table 1.1), removed with TFA, have become 
widely used in Fmoc SPPS.
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Amino acid Protecting erouD
Arg Pmc
Asn, Gin Mbh, Trt
Asp, Glu t-Bu ester




Ser, Thr, Tyr t-Bu ether
Table 1.1: Commonly used side-chain protecting 
groups in Fmoc methodology
Notable exceptions are Cys, His and Arg. Due to problems with unwanted 
disulphide formation Cys protection is often retained during cleavage from the resin 
and intial purification. It can then be removed at a later stage to allow disulphide 
formation under more controlled conditions. Consequently acetamidomethyl 
(Acm)17 (cleaved with I218, Hg2+ 17 or Ag+ 19) and S-t-Bu (cleaved under reductive
conditions20’21) have been frequentiy used.
Arg protecting groups based upon ring substituted arylsulphonyl derivatives 
such as the Mtr22 group (18) have proved the most effective.
OMe
M|  Me 0*lrVe Me^fV
Me Me' Me
SO,1 SO,1
(18) Mtr (19) Pmc
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The Mtr group has proved somewhat resistant to TFA cleavage22-24, often requiring 
extended cleavage times and the more acid-labile 2,2,5,7,8-pentamethylchroman-6- 
sulphonyl (Pmc) (19) group is now preferred25.
Histidine also presents special problems, as the basic imidazole ring can 
catalyse racémisation. N-T-trityl protection is effective for preventing racémisation 
during HOBt activation but substantial racémisation occurs if DCC or DIC is used in 
the absence of HOBt26. A superior protecting group for histidine is the N-7t-t- 
butyloxymethyl (Bum) group27 which is highly effective in suppressing 
racémisation. Unfortunately, this derivative has proved rather troublesome to 
synthesise, making it somewhat expensive and its use has remained limited.
1.1.5 The solid support
The general requirements for a suitable solid support for solid phase synthesis 
have been outlined by Erickson and Merrifield28. It must:
(a) have reactive sites at which the peptide can be attached, synthesised and
subsequently obtained in useful yield;
(b) allow good contact between peptide and reagents;
(c) be easily separated from excess reagents and by-products;
(d) be stable to the reaction conditions;
(e) minimise interactions between bound peptide chains.
As outlined above, Merrifield selected polystyrene cross-linked with 1% 
divinylbenzene. These small spherical beads are about 50 (J.m in diameter but swell 
to five or six times their original volume in organic solvents such as 
dichloromethane2 ,̂ allowing the reagents access to the peptide.
Since Merrifields original work, many other solid supports have been 
suggested. These include cellulose30'32, polypropylene membranes33 and porous 
glass34'36. Only the polyamide resins developed by Sheppard and co-workers37-38
9
have come into widespread use. These resins, when supported on kieselguhr, are 
mechanically robust and have proved suitable for continuous flow SPPS39.
1.1.5 Coupling methods
The success of the peptide bond forming reaction is obviously of crucial 
importance to the assembly of a peptide by either classical solution phase methods or 
SPPS. Accordingly, this area has attracted much attention and many coupling agents 
have been proposed40.
The selection of a suitable reagent is often dictated by the need for 
racemisation free coupling. Only a few methods have met these stringent 
requirements and passed into routine use.
Racemisation of amino acids occurs upon activation of the carboxyl group 
with an electron-withdrawing substituent (20). The mechanism41 involves the 
formation and enolisation of an oxazolone (21a). The intermediate enol (21b), which 
is presumably stabilised by its pseudo aromatic character, can subsequently convert 
into either the D- or L- amino acid derivative
O
(20) (21a) (21b)H
base r  CO
(21c)
Figure 1.6: Mechanism of racemisation 
on activation
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The various methods of activating amino acids to nucleophilic attack have been 
extensively reviewed40 and only a selection of the most prominent methods are 
presented here.
(a) Azides
Azide activation is one of the oldest methods of activating a carboxylic acid 
to nucleophilic attack42 and is relatively racemisation-free. Acyl azides can be 
generated by the diazotisation of a hydrazide using nitrous acid or alkyl nitrites43. 
Alternatively, diphenylphosphoryl azide can be used to form the acyl azide directly 
from the carboxylic acid44:
(PhO)2p ;
u h n o 2 h N3 tt
r c - n h n h 2  r c - n 3 —---------  RC02h
However, this method has the drawback of a highly toxic by-product, hydrazoic acid, 
and can suffer from the formation of urea derivatives by the Curtius rearrangement.
(b) Acid Chlorides
Although acid chlorides have been used in peptide chemistry since the turn of 
the century45, their use has generally been limited by problems with racemisation 
and other side reactions. Boc-protecting groups, for example, are not entirely stable 
to reagents used to generate acid chlorides (thionyl chloride and oxalyl chloride). 
However, with the increasing use of Na -Fmoc amino acids, the use of acid chlorides 
has been revived4^ 47.
The Fmoc group is stable to thionyl chloride and Fmoc amino acid A having 
aliphatic side chains can be isolated as stable compounds. These have been used 
successfully in solution phase synthesis but in solid phase synthesis their reactions
11
proved sluggish due to competing oxazolone formation. However, efficient coupling 
occurred on the addition of an auxiliary nucleophile e.g. HOBt. In the future, due to 
the widespread use of t-butyl side chain protecting groups, the use of acid chlorides 
is likely to remain limited.
(c) Fluorides
Recently Carpino48’49 and others50 have proposed the use of amino acid 
fluorides as isolable activated species for peptide synthesis. Acyl fluorides show 
much greater stability towards hydrolysis than the corresponding acid chlorides, 
while retaining a high reactivity towards nitrogen nucleophiles. Many Boc and Fmoc 
amino acid fluoride derivatives can be prepared from the parent amino acid 
derivatives using cyanuric fluoride (22) and these have proved effective in both 
solution and solid phase synthesis.
(d) Carbodiimides
Carbodiimides such as dicyclohexylcarbodiimide (DCC)51 (23) have been 
used for activation of carboxylic acids to nucleophilic attack since the 1950's. DCC 
was used in Merrifield's first reports on SPPS5 and has remained popular.
Although a highly successful reagent, DCC has several drawbacks. It causes 
dehydration of Asn and Gin residues52"54 and activated amino acids can 
spontaneously rearrange to form N-acyl ureas (24)55. Also, a DCM-insoluble by­
product, dicyclohexylurea (25) is formed during coupling. Other carbodiimides56"59
OII




which form more soluble ureas have been suggested and of these, 
diisopropylcarbodiimide (DIC)56-57 has found favour in SPPS.
RC02H + ^  y ~ N  = C = N —^  y
(4) DCC
O
" ^  .NH  





O O t v
R C - N - C - N H - /  )
Ô
(5) N-acyl urea
RC-NHR’ + O -C . (6) dicyclohexylurea
NH
Figure 1.7: Peptide bond and N-acylurea 
formation using DCC
(e) Anhydrides
Mixed anhydrides have been used in peptide chemistry since the 1940 s. 
Carboxylic-carbonic anhydrides have been generated from isobutyl60-61 or isopropyl 









Phosphinic-carboxylic anhydrides have been also been used. These can be 
generated with reagents such as diphenylphosphinyl chloride65, 1-oxo-l- 
chlorophospholane66, diphenylphosphinic anhydride67 and pentafluorophenyl 
diphenylphosphinate68. Although these mixed anhydrides have shown excellent 
coupling properties the long term instability of reagents used to generate them has 
limited their use.
Preformed symmetrical anhydrides (Figure 1.7) have found widespread use 
in SPPS. They have been shown to react rapidly in high yield and there is no 
ambiguity as to which carbonyl is attacked by the amine. Although some 
symmetrical anhydrides can be isolated as crystalline solids, they are usually 
prepared immediately before use with an activating carbodiimide such as DCC or
Disadvantages of symmetrical anhydrides include the already mentioned 
dehydration of Asn and Gin on treatment with DCC or DIC52'54 and high levels of 
racémisation that can occur with various His derivatives, e.g. Fmoc-His(Trt)26. Also, 
symmetrical anhydrides are wasteful of amino acid derivatives since one equivalent 







OIIs o + R'NH-C-R'NH
O
Figure 1.8: Formation of symmetrical anhydrides
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(f) Active esters
Due to some of the problems encountered in using carbodiimides and 
symmetrical anhydrides, activated esters have been widely studied. These include 
ortho- and para-nitrophenyl12-69, trichlorophenyl70’71, N-hydroxysuccinimidyl72 
and recently, l-hydroxy-4-ethoxycarbonyl-l,2,3-triazole73 esters. However, the 
esters of N-hydroxybenzotriazole (HOBt)74 (26), pentafluorophenol75"78 and 3,3- 
dihydro-4-oxobenzotriazin-3-ol (Dhbt)79’82 (27) have attracted the most attention. 
These can be prepared by treating the amino acid derivative with DCC or DIC in the 
presence of the alcohol and used either in situ or isolated as relatively stable 
crystalline solids. These esters have been used widely and have produced efficient 
coupling with low levels of racemisation.
O
OH
(26) HOBt (27) Dhbt
(g) Other coupling agents
The successof carbodiimides has prompted the search for other reagents for 
the in situ activation of carboxylic acids. Compounds based upon benzotriazole 
phosphonium salts have found wide use. The first of these, benzotriazolyloxy- 
trisdimethylaminophosphonium hexafluorophosphate, BOP (28), was developed by 
Castro83, but has the disadvantage of producing highly toxic hexamethyl 
phosphotriamide as a by-product. The pyrrolidine analogue, PyBOP (29), was 





0  — P(NMe2)3
i +
O—P
(28) BOP (29) PyBOP
Knorr85’86 introduced benzotriazole tetramethyluronium salts, HBTU (30) 
and TBTU (31), as coupling agents while more recently Coste87 has introduced 
PyBroP (32), which has been shown to be highly effective for even hindered 
couplings such as those of N-methyl amino acids.
All of the reagents mentioned above can be used with an auxiliary 
nucleophile such as HOBt and the approximate order of reactivity is88:
BOP/HOBt > DIC/HOBt > DIC/Dhbt > DIC/Pfp
1.1.7 Peptide-resin link. Synthesis of C-terminal acids
With the advent of Fmoc methodology and the use of t-butyl side chain 
protecting groups came a need for more acid-labile linkers. The Wang linker89 (33) 
was originally designed for the synthesis of protected fragments in combination with 
the highly acid-labile Na -biphenyloxycarbonyl protecting group but it has found 
more general use in Fmoc SPPS.




O C H ,-©
The first amino acid is introduced by activation as a symmetrical anhydride and 
coupled to the resin-bound hydroxyl group in the presence of a catalytic amount of 
DMAP. The peptide can be cleaved from the resin in mild conditions (TFA), the 
incipient carbocation being stabilised by the para-alkoxy group.
Disadvantages of this linker are 2,5-diketopiperazine formation with C- 
terminal proline and partial racémisation with C-terminal Cys and His. Both of these 
problems can be circumvented using the highly acid labile 2-chlorotritylchloride 
linker (21)90;
Diketopiperazine formation is suppressed by steric hindrance at the C-terminus, 
while racemisation is not an issue since the first amino acid is introduced as a 
diisopropylethylammonium salt. The chlorotrityl linker also offers the possibility of 
cleaving the side-chain protected peptide from the resin for use in fragment 
condensation.
1.1.9 Synthesis of C-terminal amides and other C-terminally functionalised 
peptides
Many biologically important peptides have a C-terminal amide functionality 
(e.g. hormones and many neurotransmitters). This, and the ability to modify peptide
(34)
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C-termini for biological studies makes the synthesis of peptide C-terminal amides 
highly desirable.
Peptide C-terminal amides have been synthesised by ammonolysis of the 
peptide-resin ester linkage91. Similarly, other C-terminal derivatisations have been 
accomplished by using different nucleophiles e.g. hydrazine (hydrazides)92, amines 
(N-alkyl amides)93’94 and alcohols (esters)95. The rate of cleavage however can be 
slow at hindered amino acids and prolonged exposure of peptides to ammonia can 
have undesirable consequences such as racémisation, (3-aspartimide formation and 
lysis of amide bonds96. These problems can be circumvented if the peptide amide 
can be generated upon cleavage of the peptide-resin bond:
O O
R - C - N H - ®  TFA ► R -C -N H 2 + ®  +
Approaches compatible with Boc methodology have been reported and these 
include the benzhydrylamine linker (35) and (36) suggested by Tam97 and 
Marshall93 respectively.
Similar approaches have been applied in Fmoc methodology, although much 
more acid-labile linkers are required. This has usually been accomplished by 
additional ortho- and para- alkoxy substituents in the benzylic linker system. Several 
such systems have been developed (Table 1.2). Although the PAL linker (39) 
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Table 1.2: Linkers developed for the 
synthesis of peptide amides
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trialkoxybenzyhydrylamine linker (37) introduced by R ink" seems to have gained 
the most popularity.
Linkers have also been designed to offer other C-terminal functionalities. 
These include esters and hydrazides (Table 1.3), but this area has received relatively 
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Table 1.3: Linkers for the synthesis of 
C-terminal hydrazides and esters
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1.1.10 Synthesis of protected fragments
The mild procedures developed for Fmoc peptide chemistry have resulted in 
a number of linkers from which the peptide can be cleaved by mild acidolysis 
leaving side chain protected peptides, useful for fragment condensation reactions.
The chlorotrityl linker92 (34) has already been mentioned in this context but 
other examples include the alcohol variant of the Rink linker100 (30), the SASRIN 
linker109 (44) and the recently introduced HMPB linker110 (45):
CH2OH c h 2o h
y  y
OCH2C O - ©  0(CH2)3C 0 —( p )
(43) (44) (45)
The HMPB linker shows slightly more acid stablity than the Rink linker and enables 
acidic coupling reagents, such as HOBt, to be used without cleavage of the peptide- 
resin linkage.
Other approaches have been employed for the synthesis of protected 
fragments and these include the fluoride labile linkers of Ramage111 and Barany112, 
and photolabile linkers11̂ .
1.2 Peptide Purification
Although the synthesis of peptides on a solid phase support has developed 
into a highly sophisticated science, the product cleaved from the resin is seldom 
pure. This may be due to side reactions that can occur during assembly or cleavage 
or due to incomplete coupling steps. All of these factors combine to produce an 
impure product. Often the crude material may contain only a minor amount of
OH
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contaminants but nevertheless, one or more purification steps are required to obtain 
the peptide in pure form.
A whole range of purification techniques are available to purify synthetic 
peptides. While many were initally developed for the purification of biological 
molecules isolated from natural sources, others have been designed specifically to 
overcome problems associated with synthetic peptides. A few of the more common 
techniques are outlined below.
1.2.1 Gel Filtration Chromatography
Gel filtration utilises a polysaccharide solid matrix with closely defined pore 
sizes. Separation depends upon the relative size (or more precisely hydrodynamic 
volume) of the constituents of the mixture. Larger molecules are completely 
excluded from the pores of the solid support and elute with the void volume of the 
column. Smaller molecules have access to the pores in different degrees and are 
retained depending on the extent of this access.
A variety of gel filtration media are available based on dextran (sephadex, 
sephacryl) or agarose. The amount of cross-linking in these materials can be varied, 
giving rise to solid supports with different pore and particle sizes.
Gel filtration lends itself readily to the separation of of peptides from lower 
molecular weight species such as scavengers or salts but with careful choice of gel 
and operating conditions it can also be used for the fractionation of peptides.
1.2.2 Ion-exchange Chromatography
Proteins and peptides carry both positive and negatively charged groups. 
Positive charges are carried by basic groups (N-terminus, lysine, arginine, histidine) 
which can be protonated, while negative charges are carried by ionised acidic groups
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(C-terminus, aspartic and glutamic acids). The net charge on a peptide depends on 
the relative numbers of these groups and varies with pH.
In ion exchange chromatography the different charges on peptides and 
proteins is used as a basis for separation of the components of a mixture. Peptides 
can be bound to an ion-exchange column by electrostatic interactions with an 
immobilised inorganic counter ion. Subsequent elution is accomplished by bringing 
the pH closer to the isoelectric point, pi, of the peptide or by changing the ionic 
strength of the eluent. In praise a gradient which varies either or both of these 
factors can be used to effect peptide purification.
1.2.3 Reverse Phase High Performance Liquid Chromatography (RP-HPLC)
Separation by RP-HPLC relies upon the hydrophobic interaction of the 
components of a mixture with long chain alkyl groups, covalently bound to a solid 
support. Usually these are Cg or Cjg alkyl chains bound to silica but other 
immobilised organic moieties are available (e.g. C3, C4, Cg and phenyl).
The mobile phase consists of water, a miscible organic solvent and dissolved 
buffers and salts. Separation is achieved by a gradient elution, gradually increasing 
the proportion of the organic component (usually acetonitrile or isopropanol) in the 
aqueous eluent. Rapid separations with high resolution can easily be achieved and 
RP-HPLC is probably the most widely used technique for the purification of 
synthetic peptides.
A drawback to the method has been the instability of the silica matrix at pH 
values greater than 7. This can be a problem with acidic peptides which are insoluble 
in the buffers normally used. However, non-silica based packing materials 




Molecules such as proteins and peptides carry out their biological function by 
a highly specific binding to substrates. This interaction has been utilised for the 
purification of biomolecules in affinity chromatography, where a ligand L, 
immobilised on a solid support, can be used to separate a substrate S, for which it 





Figure 1.9: Affinity Chromatography
Immobilisation of the ligand is accomplished by activating hydroxyl groups 
on the solid support (typically agarose) to attack by nucleophiles on the ligand 
(amino, thiol). Activating species include cyanogen bromide and sulphonyl chloride.
Once the mixture has been applied to the column and the non-specifically 
bound components eluted then the substance of interest can be eluted. This is usually
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accomplished by a change in the solvent conditions e.g. ionic strength, pH, use of
dénaturants, or temperature etc.
This method can be very powerful, and may be used to obtain the desired
substance in high purity by a single step purification, even when present in low
abundance. For example, Memfield5 used immobilised polyclonal human leucocyte 
interferon antibodies for the purification of synthetic human leucocyte interferon
and <*2 (166 and 155 residues respectively). However, the more general application
of this method to synthetic peptides can be limited by the availablity of suitable 
ligands.
1.2.5 Affinity labels for the purification of peptides
One of the main problems in peptide purification, particularly for long 
sequences, is the removal of accumulated truncated peptides. Truncated peptides are 
formed when coupling reactions fail to go to completion, for reasons such as steric 
hindrance, folding or inter-chain aggregation. The N-termini of these truncations are 
routinely capped with acetic anhydride to ensure they play no further part in 
synthesis, so that at the end of the synthesis the crude peptide consists largely of the 
desired sequence and these acetylated failure sequences, the separation of which can 
prove difficult using conventional chromatographic techniques.
In a variation of the affinity method described above, several workers have 
suggested methods whereby the N-terminus of the desired peptide is derivatised with 
a group capable of a covalent or affinity binding to a solid suport. This allows the 




Early efforts on the the design of affinity tags concentrated on the 
introduction of polar groups to enhance the charge on the peptide and hence its 
retention on ion exchange columns.
Suzuki114 introduced an additional lysine onto the N-terminus of small 
fragments of the B chain of human insulin. After purification on a carboxymethyl- 
cellulose column the amino acid extension was removed by an Edmann degradation.
Using a similar strategy, Merrifield115 functionalised peptide N-termini with 
a sulphonic acid derivative of the Fmoc group (46) to facilitate purification on a 
DEAE-cellulose column. This group had the advantage of being readily cleaved 




Reciprocal strategies have also been suggested, whereby polar anhydrides are 
used in place of acetic anhydride for capping the truncated peptides. 3-Nitrophthalic 
anhydride116, 2-sulphobenzoic acid anhydride117 and 3-sulphopropionic 
anhydride118 have all been used in this manner when it was the truncations that were 
strongly retained on ion exchange columns and the desired peptide eluted.
Although all the above cases were successful, only relatively short peptides 
(<10 residues) were purified. It is doubtful whether this methodology could be 
applied to longer peptides where there will be intrinsically more polar groups 
present, diluting the effect of the added polar handle.
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(b) N-terminal thiol groups
The reactivity of thiol groups i.e. nucleophilicity, disulphide formation and 
metal-ion complexation have all been exploited to selectively bind peptides to solid
supports.
The first such method was suggested by Merrifield119 and involved 
extending the peptide by an additional two residues, Cys-Met-. The cysteine moiety 
enabled the peptide to be selectivley bound to an organomercury-sepharose column, 
while the methionine group enabled the two residue extension to the peptide to be 
selectively removed with cyanogen bromide. This was used successfully for the 
purification of ribonuclease (111-124), but is not readily applicable to other cysteine 
and methionine containing peptides.
In a similar method, Funakoshi et a /120 derivatised the N-termini of the 
completed peptide with a thiol-containing group. This enabled the peptide to react 
selectively with an iodoacetamide resin. After elution of the acetylated truncated 
impurities, the free peptide could be obtained on treatment with base, the base- 
lability being conferred by an electron-withdrawing sulphone group in the affinity 
tag (Figure 1.10). This method has been successfully applied to the purification of 
cholecy stokinin (33 residues) and human growth hormone-releasing factor (44 
residues).
Lansbury121 recently suggested the use of the N-terminal (2-[(2- 
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Figure 1.10. Affinity-type purification of synthetic 
peptides on iodoacetamide resin120
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The disulphide, or reduced thiol form, was used to bind the peptide to a polystyrene 
support derivatised with a disulphide (disulphide exchange), alkyl thiol (oxidation - 
disulphide formation), mercury (II) trifluoroacetate (complexation) or iodoacetamide 
functionality (nucleophilic substitution). Although this method is unlikely to prove 
generally applicable, since the NpSSPeoc group is only stable to 1% TFA for ca. 1 
h, it was useful in this instance for the purification of a number of hydrophobic 
protected peptide fragments, species which can often be difficult to purify by 
conventional methods due to their poor solubility in aqueous media.
(c) Avidin-biotin
The affinity of biotin for avidin has been well documented122 and the«, has 
been a number of applications of the use of biotin as an affinity tag for the 
purification of synthetic peptides. For instance, Lobl et a/123 purified several 
biotinylated fragments of interleukin-lp using this method, the largest being [Asp- 
205]-interleukin-ip (117-269), present in less than 1% yield.
A further example was reported by Heinrikson for the purification of 
chemically synthesised SIV-protease124 (99 residues). Here, the SIV sequence was 
extended by eight residues, corresponding to the next amino acids in the sequence of 
the natural SIV protease precursor. The N-terminus of the completed chain was 
biotinylated and the peptide purified on a* avdvrragarose column. The peptide was 
then folded into its active conformation when the synthetic SIV protease 
autocatalytically cleaved the eight amino acid extension, giving a pure sample of 
synthetic SIV protease after removal of the cleaved fragment.
In these examples the biotin tag was retained or cleaved by a mechanism 
specific to the peptide. For more general applications, the affinity label should be 
readily removed after purification. In this respect Wilchek125 has employed 
biotinylated methionine which can be cleaved with cyanogen bromide, although this
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suffers from the same problem of other similar applications in not being useful for 
sequences containing other methionine residues.
A number of other affinity labels have been developed over the years. For 
example highly immunogenic dinitrophenyl tags have been used, which can be 
bound to a column derivatised with anti-dinitrophenyl antibodies126. Mascagni127 et 
al have developed a modified Fmoc group, incorporating an amino decanoic acid 
dipeptide at the 4-position, which imparts hydrophobic character to the peptide, 
resulting in enhanced retention times on RP-HPLC. This proved useful for the 
purification of synthetic HIV-1 p24 GAG (270-373) (104 residues), and when taken 
with the examples above, would seem to augur well for the future use of affinity tags 
for the purification of chemically synthesised proteins.
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CHAPTER 2
AFFINITY PURIFICATION OF SYNTHETIC PEPTIDES 
ON POROUS GRAPHITISED CARBON
2.1 Design of an affinity tag for purification of peptides on porous graphitised 
carbon
Porous graphitised carbon (PGC) is a chemically and mechanically robust 
two dimensional graphite with a large surface area (ca. 150 m2/g)128. It is made by 
polymerising a phenol-hexamine mixture within the pores of silica gel and 
pyrolysing the resin in an atmosphere of nitrogen. The silica template is then 
dissolved and the residue heated to a temperature in excess of 2000°C. This material 
was developed by Knox128 as a solid support for HPLC and has proved to be a 
strong adsorbent for hydrophobic species, in particular for large flat molecules129.
Inspired by this work, Ramage and R a p h y 1 30^31 attempted to exploit the 
hydrophobicity of this substance for the purification of synthetic peptides. They set 
out to design an aromatic molecule that would adsorb strongly to PGC. If the N- 
terminus of a peptide could be tagged with this species then in principle the peptide 
could be separated from truncated sequences by selective binding to PGC. Such a 
molecule would:
(a) be sufficiently large and flat, so as to be strongly retained on PGC;
(b) be stable to conditions used to cleave the peptide from the resin
(TF A/scavengers);
(c) ideally have a chromophoric group (>350 nm) to allow UV monitoring;
(d) be readily removed from the peptide when required.
Fused benzofluorenes meet these requirements and Ramage and Raphy synthesised 
two such systems, dibenzofluorene and tetrabenzo[a,c,g,i]fluorene. Dibenzofluorene
31
derivative (48) failed to exhibit sufficiently strong retention on PGC, but the 
tetrabenzo[a,c,g,/]fluorene system (49) showed excellent properties.
(48) (49)
The tetrabenzo[a,c,g,i]fluorene group was incorporated into an amino acid, 
glycine, as a base-labile Na -urethane protecting group, tetrabenzo[a,c,£,i]fluorenyl- 
17-methoxycarbonyl (Tbfmoc). Tbfmoc-Gly-OH (50) was used as the N-terminal 
amino acid in the solid phase synthesis of several peptides (6, 23 and 42 residues) 
and these were found to selectively bind to PGC in the presence of acetylated 
truncated sequences. Following separation of the truncations, the peptides could be 
released from the PGC by removal of the Tbfmoc group with base, clearly 
demonstrating the potential of this methodology for peptide purification.
OII
Further studies on the preparation and application of Tbfmoc derivatives are 
now reported.
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2.2 Synthesis of tetrabenzo[a,c,g,i]fluorene derivatives. Historical perspective
Many procedures have been described for the synthesis of fused 
benzofluorene derivatives (51) and these have been reviewed132’ 133.
Of the many fused benzofluorenes reported, derivatives of 
tetrabenzo[a,c,g,i]fluorene (52) have received relatively little attention and until 
recently only two syntheses had been described, both due to Martin and co- 
workers134«135.
The first route (Figure 2.1) requires a multistep synthesis to obtain the 9,10- 
disubstituted phenanthrene starting material. Thereafter, tetrabenzo[a,c,g,i[fluorene 
(5) is obtained in low overall yield (<12%)134.
(52)
Figure 2.1
In the second synthesis135, although reasonable yields are quoted for the earlier 






Hopkinson et a /136 and others137’138 have studied the rearrangement of 




Figure 23 : Rearrangement of electron-deficient 
diaryl cations136
Recently, Ramage and Raphy130-131 exploited this reaction for the synthesis of 17- 











A low overall yield (10%) after several chromatographic separations made this route 
unattractive for obtaining multigram quantities of (56). Initial studies therefore 
concentrated on improving the synthesis of (56), a key intermediate in the synthesis 
of Tbfmoc amino acids and peptides (57).
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O -C -N H -R
R = -NH-Peptide, 
-NHCHR'COOH
(57)
2.3 Synthesis and reactions of tetrabenzo[a,c,g,i]fluorene (52)
Carpino has reported the synthesis of 9-fluorenyImethanol (59) by reacting of 
the anion of fluorene (58) with ethyl formate, followed by in situ cross-Cannizaro 
reduction of the intermediate aldehyde139:
It was thought that an alternative route to 17-tetrabenzo[a,c,g,/]fluorenylmethanol 
(56) might be offered by an analogous reaction with tetrabenzo[a,c,g,i]fluorene (52) 
and an efficient route to this molecule was sought
The Grignard reagent of 9-bromophenanthrene was generated in ether and 
following addition of ethyl formate, alcohol (60) was isolated in ca. 40% yield. The 
yield improved to 52% in THF which proved a better solvent for both starting 
material and intermediates.
Attempts were then made to cyclise alcohol (60) to form 
tetrabenzo[(2,c,g,i]fluorene (52). Both PPA13® and Eaton's reagent14® gave 
intractable brown solids, while with d^SO ^A cO H 13® only traces of the fluorescent


















Figure 2.6: UV spectra of —  (52) (2.73 x 10'5M) 
and — (61) (3.01 x 10'5M)
'M
smoothly, upon treatment of (60) with TFA in DCM and (61) was isolated in 90% 
yield (Figure 2.5).
Initially the product isolated from the TFA cyclisation reaction was thought 
to be (52). The isolated material had a similar melting point to the literature value for 
(52) and the mass spectrum showed the expected molecular ion at 366. However, the 
NMR spectrum showed a more complex aromatic splitting pattern than would 
have been expected for a symmetrical structure such as (52) and only a one proton 
signal at 5 5.42 ppm was observed where structure (52) would require two. Also, the 
UV spectrum (Figure 2.6) showed subtle differences from the published 
spectrum134. Based upon these observations and taking into account the possible 
intermediates that would be formed via the mechanism shown in figure 2.7, structure 
(61) was assigned, and this was supported by later work (see section 2.4).
Figure 2.7: Cyclisation of to-phenanthrylmethanol (60) in acid and 
base-catalysed rearrangement to tetrabenzo[a,c,g,i]fluorene system
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Previous reports on analogous cyclisations136-138, have referred only to the 
isolation of the expected fluorene system, invoking a hydride shift137 as a 
mechanistic explanation for its formation. This would not appear to be the case, at 
least in this instance, where the formation of the fluorene system requires a 
deprotonation and reprotonation, catalysed by base (Figure 2.7).
The next stage of the synthesis required the reaction of the anion of (61) with 
a suitable electrophile. Treatment of (61) with ethyl formate in the presence of 
sodium hydride followed by an aqueous formaldehyde work-up139 failed to produce 
any of the desired alcohol (56). Quenching the reaction with water in place of 
formaldehyde showed that none of the expected aldehyde intermediate (62) had been 
formed.
Instead, a dark red compound, ketone (63) was isolated. This was presumably 
formed by the air oxidation of the anion of (61) and in fact this proved to be a 
reasonably efficient route to ketone (63):
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Attempts to react the anion of (61) with another suitable electrophile, methyl 
chloroformate also proved fruitless and ester (64) could only be isolated in poor 
yield (20%).
In light of the poor reactivity of the anion of (61), with suitable electrophiles, 
this strategy was abandoned for the synthesis of 17- 
tetrabenzo[<2,c,g,/']fluorenylmethanol (56). However, it may provide a convenient 
route to other 17-substituted tetrabenzo[a,c,g,f]fluorene derivatives. For instance, 
(61) was found to undergo a Michael addition with ethyl acrylate to give ester (65):
Reduction of this ester to an alcohol and esterifcation of the alcohol with a chiralA
acid such as phenylglycine would give a chiral compound that could be adsorbed 
onto PGC. This might be useful for the resolution of racemates, in a similar fashion 
to the modified silica columns reported by P irk le^l.
In addition, Wahl has recently reported that the reaction of (61) with allyl 
bromide or benzylic bromides takes place in reasonable yield142. For example (66)
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was synthesised as a key intermediate in the synthesis of chlorotrityl derivative (67) 
which was used as a hydrophobic 5'-OH protecting group for the purification of 
oligonucleotides by HPLC142.
2.4 Synthesis of 17-tetrabenzo[a,c,g,t]fluorenyImethanoI (56)
Attention now switched to the strategy developed by Raphy130 (Figure 2.4) 
to see if improvements to the overall yield could be achieved by applying the 
chemistry developed in the synthesis of tetrabenzo[a,c,g,i]fluorene (52), (section 
2.2).
9-Phenanthryl magnesium bromide was treated with ethyl oxalate, giving 
alcohol (54) in a reasonable yield of 57% (Figure 2.8). This contrasts with the 
reaction of 9-phenanthryllithium reported by Raphy130, where a one pot synthesis of 
(54) failed, the reaction having to be carried out in two separate reactions with a 
combined yield of 29%.
This reflects the relative reactivities of the two aryl-metallic reagents. Ethyl 
oxalate has two ester groups and could conceivably react with an organometallic 
reagent to form five possible products:
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Presumably, the Grignard reagent is sufficiently selective to allow the two step 
reaction to be carried out in one-pot while a similar reaction with the organolithium 
reagent produces a complex mixture.
Alcohol (54) was treated with TFA/DCM, when cyclisation occurred in good 
yield. As in the synthesis of tetrabenzo[a,c,g,i]fluorene (52), mainly the 86-H isomer 
(68) was formed. This had a similar UV spectrum to that of (61) (Figure 2.6), and 
showed a distinctly different ^  NMR spectrum to isomer (55) (Figures 2.9 and 
2.10), which had been synthesised by Raphy130. Isomérisation of (68) to (55) 
occurred rapidly on treatment with EtjN/DCM.









Figure 2.8: Synthesis of 17-tetrabenzo[a,c,g,/]fiuorenylmethanoI
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Additional evidence for the assignment of structures (68) and (55) was 
obtained from NOE experiments (Figures 2.9 and 2.10). In each case, irradiation of 
the ethyl ester CH2 and the 5-membered ring CH were carried out and the NMR 
difference spectrum plotted. In isomer (68), iradiation of the CH2 produced positive 
NOE's for the two one proton resonances centred at 8.11 ppm and 7.73 ppm (H-l 
and H -l6), while irradiation of the 86-H gave a positive NOE at a different one 
proton aromatic resonance centred at 8.01 ppm (H-8). This was consistent with 
structure (68), the ethyl CH2 and 86-H being located close to different aromatic
protons.
When a similar experiment was performed on isomer (55), the same aromatic 
resonance was affected in each case (equivalent protons H-l and H-16), in line with 
the much closer proximity of the ester and 5-membered ring CH required by 
structure (55).
After reduction of (55), 17-tetrabenzo[a,c,g,/]fluorenylmethanol (56) was 
obtained in an overall yield of 41% (Figure 2.8), a four-fold increase on the original 
synthesis (Figure 2.4)13̂  and requiring no chromatographic separations.
UV showed that remarkably little isomérisation occurred when (68) was used 
as substrate for the DIBAL reduction and 86-H isomer (69) could be converted into 
the desired alcohol on base treatment. However, the overall yield on carrying out the 
steps in this order was lower than the sequence shown in Figure 2.8.
No problems were encountered on scaling up the reactions and access to 30-40 g 
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Figure 2.9: *H NMR spectrum (360 MHz) 
and NOE experiment on isomer (68)
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Figure 2.10: *H NMR spectrum (360 MHz) 
and NOE experiment on isomer (55)
2.5 Synthesis of Na -17-tetrabenzo[a,c,g,i]fluorenylmethoxycarbonyl (Tbfmoc) 
amino acid derivatives
Raphy130 used alcohol (56) to synthesise several reagents for the introduction 
of the Tbfmoc group onto the Na  position of amino acids.
Chloroformate, Tbfmoc-Cl, (70) was reportedly difficult to synthesise 
directly from alcohol (56), although it was obtained in low yield by the reaction of 
its TMS ether with phosgene. Succinimide carbonate (71) was also reported to be 
difficult to synthesise and isolate. However, p-nitrophenyl carbonate (72) can be 
obtained in good yield and isolated as a stable crystalline solid.
(70) Tbfmoc-Cl; X  = Cl
O
J S
(ni) Tbfmoc-ONSu; X =  — 0 ~N I
O
Tbfmoc-ONp; X  = — Q — NQ2
(72) was shown to be unreactive towards the N-termini of resin-bound 
peptides130. The alternative strategy of preparing Na -Tbfmoc amino acids which 
could be used as the final residues in solid phase peptide synthesis was employed. 
Two Tbfmoc amino acids, Tbfmoc-Gly-OH (50) and Tbfmoc-Phe-OH, were 
reported and these were made from the acetate salts of the parent amino acid t-butyl 
esters (Figure 2.11).
Clearly, to allow general application of the affinity of the Tbfmoc group for 
PGC to the purification of peptides, then all 20 Na -amino acids would need to be 
available. With this goal in mind, synthesis of a number of Tbfmoc amino acid 
derivatives was undertaken using the nitrophenyl carbonate (72).
OII
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Figure 2.11: Synthesis of Tbfmoc amino adds
2.5.1 Alternative routes to Tbfmoc amino acids
Attempts to simplify the synthesis of Tbfmoc amino acids were made by 
employing Schotten-Baumann conditions. It was hoped this would obviate the need 
for expensive amino acid t-butyl esters and would also allow one step syntheses of 
many of the simpler Tbfmoc amino acids.
As a trial, glycine was taken in dioxane/aqueous Na2C03 and added to a
solution of Tbfmoc-ONp (72) in dioxane. Although keeping the hydrophobic 
carbonate (72) and the hydrophilic amino acid mutually soluble proved troublesome, 
Tbfmoc-Gly-OH was obtained in a moderate yield of 45%. This compares 
unfavourably with Raphy's two step synthesis from GlyO*Bu (Yield 79%), but 
nevertheless offers a much quicker and more economical route to Tbfmoc-Gly-OH 
(50).
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Encouraged by this result, attempts were made to extend this reaction to other 
amino acids (leucine, valine and phenylalanine). Unfortunately, this met with little 
success. Although traces of products were detected by TLC, reactions of (72) with 
these more hindered amino acids proceeded much more slowly. The main product in 
each case was shown by TLC to be the red-orange coloured fulvene (73)130, formed 
by decompostion of carbonate (25) in basic reaction conditions:
This method was not pursued further.
One of the main problems in synthesising Tbfmoc amino acids seemed to be 
the high base-lability of derivatives such as (72) that are required. If the base-lability 
of the Tbfmoc group could somehow be masked, or introduced at a later stage, then 
this should lead to higher yielding reactions with amino acid derivatives. This would 
be achievable if the cyclisation of the fe-phenanthryl system (54) to the 




This would necessitate the preparation of an activated carbonate of the form
X = activating group 
e.g. Cl, O-p-nitrophenyl
(74) shows the tertiary alcohol group protected as a methyl ether, which would be 
desirable to prevent any intramolecular cyclisation that might occur if the alcohol 
had remained unprotected (75):
Compound (54) was taken as starting material, available in large quantities 
via the reaction shown in Figure 2.8. Initial attempts to protect the tertiary alcohol 
with Mel using either NaH or KC^Bu as base failed, with only starting material 
being isolated. However, the methyl group was finally introduced with KOH- 
DMSO-Mel, giving ether (76) in 57% yield (Figure 2.12). TLC experiments showed 
that the ether did not affect the propensity of the molecule to cyclise in TFA/DCM to 
form ester (68). The ester group of (76) was therefore reduced to alcohol (77) in
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(78) was used to prepare the urethane derivative of n-butylamine (79) as a model 
compound:
„  F F 
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Trials were carried out on the cyclisation of this compound to the tetrabenzofluorene 
system in TFA/DCM. Although TLC showed the initial appearance of the 
fluorescent product, all attempts to isolate it failed, the deep red-orange fulvene (73) 
being among several products present. This would appear to be due to the formation 
of the 8£-H isomer (80). Unlike the desired Tbfmoc-derivative, the 8Z?H-isomer (80) 
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Unfortunately, attempting to isomerise (80) to the Tbfmoc-derivative by 
treatment with mild base, N,N-dimethylaniline, failed. Presumably, in this case, 
base-catalysed decomposition occurs in preference to isomérisation:
At this stage this approach to the synthesis of Tbfmoc amino acids was abandoned. 
However, in the future a similar approach might prove useful with other fused 
benzofluorene systems. This would provide a novel approach to lysine side-chain 
protection, when treatment with TFA (e.g. during cleavage of other side-chain 
protecting groups) would effect cyclisation of the Ne-protecting group:
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This would leave the peptide protected on the Ne-amino function of lysine with a 
base-labile benzofluorene urethane. This would find use in fragment condensation 
where selective protection of the lysine side-chain is needed. However, this would 
require a benzofluorene system where the initially formed isomer, e.g. (81), 
spontaneously rearranges to the required fluorene system (82):
Some preliminary trials were carried out on ethyl benzilate (83), with a view 
to developing such a protecting group, but this compound failed to cyclise in TFA, 






2.5.2 Synthesis of Tbfmoc-Met-OH
Affinity tags have previously been introduced onto the N-termini of peptides 
as derivatives of methionine115’125, since the additional methionine residue can be 
selectively cleaved with cyanogen bromide after purification. This strategy could be 
extended to the synthesis of Tbfmoc peptides, whereby the peptide N-terminus could 
be capped with Tbfmoc-Met-OH.
In addition, methionine forms the N-terminus of ubiquitin, a small protein 
(76 residues) which was the subject of on-going synthetic and structural studies in 
this laboratory. Of all the amino acids, Tbfmoc-Met-OH was considered the most 
important at this stage and its synthesis was undertaken.
Raphy1511 had previously prepared Tbfmoc-Met-OMe, however it was not 
possible to selectively cleave the methyl ester in the presence of the Tbfmoc group.
In contrast, Tbfmoc-Met-O^u should cleave readily in TFA to liberate Tbfmoc- 
Met-OH. Methionine t-butyl ester is not commercially available but its synthesis has 
been described from Na -phthalyl methionine143. This compound was therefore
prepared by the literature procedure from methionine and phthalic anhydride144. The 
t-butyl ester was then made by the standard method (isobutylene/cH2S04) and the
phthalyl group removed with hydrazine to give M et-O^u as a colourless liquid, 
after distillation.
M et-O^u was then taken in DCM with N,N-dimethylaniline and nitrophenyl 
carbonate (72). After several days, an intensely red-orange coloured solution had 
formed, indicating extensive decomposition of the carbonate (72) to fulvene (73). 
None of the required product was detected by TLC.
In the synthesis of Tbfmoc-Gly-OH, Raphy130 had employed the acetate salt 
of Gly-C^Bu. The reaction was therefore repeated in the presence of one equivalent 
of acetic acid. After several hours TLC showed a new fluorescent spot and after^ t€- 
days the product was isolated and shown to be the desired compound, Tbfmoc-Met- 
QtBu.
53
The successful synthesis of Tbfmoc-Met-C^Bu, in the presence of one 
equivalent of acetic acid, served to outline the importance of adequately buffering 
the reaction to suppress the basic nature of the amine group of the amino acid 
derivative. In the absence of the acetic acid, the basic nature of the amine simply 
serves to cleave nitrophenyl carbonate (72) to give fulvene (73). The acetate salt of 
Met-O^Bu was therefore prepared and used in further syntheses of Tbfmoc-Met- 
O’Bu, giving the product in moderate yields of 36-39%.
Cleavage of the t-Bu ester was then attempted in 95% TFA/5% H20. TLC
after 3 h showed the reaction to be complete. After removal of the TFA in vacuo a 
solid was obtained on trituration with ether. TLC showed several components and 
further work-up of the crude product exacerbated the problem. Methionine has 
previously been reported to be susceptible to photooxidation in the presence of 
sensitising agents such as benzophenone145, and it may be that the Tbfmoc group 
was acting as a photosensitising agent, promoting side reactions such as oxidation.
In an effort to suppress any methionine oxidation, the reaction was repeated 
in the presence of a mixture of EDT and sulphides (ethyl methyl sulphide and 
thioanisole). In this case, the product, Tbfmoc-Met-OH was isolated in 85% yield 
when TLC and HPLC showed only traces of by-products.
2.5.3 Synthesis of Tbfmoc-Ala-OtBu, Tbfmoc-Ile-OtBu, Tbfmoc-Leu-OtBu and 
Tbfmoc-Val-OtBu
Ala-O'Bu, Ile-C^Bu, Leu-C^Bu and Val-C^Bu are all commercially available 
compounds. This and the fact that no side-chain protecting groups are required made 
the Tbfmoc derivatives of these amino acids obvious synthetic targets.
The acetate salts of each amino acid t-butyl ester were prepared and these 
reacted with carbonate (72) in the presence of N,N-dimethylaniline to give the Na -  










Table 2.1: Yields of Tbfmoc amino 
acid t-butyl esters
2.6 Synthesis and purification of Tbfmoc peptides
2.6.1 Synthesis of Tbfmoc Human Gastrin Releasing Peptide
Having synthesised a range of Tbfmoc amino acid derivatives, a suitable 
peptide target was sought to allow study of both the coupling of the Tbfmoc-amino 
acids and behaviour of the resulting Tbfmoc-peptides on PGC.
Human gastrin releasing peptide146 (hGRP) (84) was selected since it is of 
reasonable size (27-residues) and has an N-terminal valine, a Tbfmoc derivative of 
which was now available.
The peptide was synthesised minus its N-terminal valine using amide resin 
(108). An Fmoc loading test147 after coupling of the final amino acid (residue 2, 
proline) indicated that assembly of the peptide on the resin had been achieved in 
77% yield.
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Tbfmoc-Val-OH was obtained in 90% yield by treatment of Tbfmoc-Val- 
C^Bu with 95% TFA/5% H20. This was then coupled by sonicating 5 equivalents of
its HOBt ester in dioxane with the resin bound hGRP (2-27). A small sample of the 
resin-bound Tbfmoc-hGRP was then taken and the incorporation of the Tbfmoc 
group estimated by the UV method developed by Raphy130. This indicated a 
dissapointingly low coupling efficiency of 49%. Tbfmoc-Val-OH was therefore 
recoupled with a further 5 equivalents of HOBt ester but only a slight increase (53%) 
in Tbfmoc incorporation was observed.
Removal of the side-chain protecting groups and cleavage of the peptide 
from the resin was accomplished using TFA in the presence of water, EDT, ethyl 
methyl sulphide, thioanisole and phenol. After concentration of the cleavage 
mixture, the crude Tbfmoc peptide was precipitated with ether. Encouragingly, an 
analytical HPLC of the crude material indicated considerably better incorporation of 
Tbfmoc-Val-OH than had been originally estimated. Only one main peak was 
observed (Figure 2.13) when a large truncated peptide peak (hGRP 2-27) would have 
been expected had a coupling efficiency of only 53% been achieved. This suggested 
serious shortcomings in the UV monitoring method for estimating Tbfmoc coupling 
efficiency developed by Raphy13̂  (see also section 2.6.3).
2.6.2 Behaviour of Tbfmoc hGRP on PGC
A solution of the crude Tbfmoc peptide was taken in 50% aqueous 
CH3CN/0.5% TFA and applied to a PGC column (particle size 50-100 (im). The
column was subjected to the washing protocol outlined below and the eluent 
monitored by HPLC :
1. 50% aqueous CH3CN/0.5% TFA (50 ml)
2. 50% aqueous CH3CN (2 x 50 ml)
3. Tbfmoc deprotection: 50% aqueous CH3CN/
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1% piperidine(50 ml), 30 min
4. 50% aqueous CH3CN (20 ml)
5. 50% aqueous CH3CN/0.5% TFA (50 ml)
6. 60% aqueous CH3CN/0.5% TFA (50 ml)
7. 70% aqueous CH3CN/0.5% TFA (3 x 50 ml)
Analysis of the eluent showed that the Tbfmoc peptide bound strongly to the 
column, while non-Tbfmoc material was eluted in the filtrate and washes 1,2. The 
Tbfmoc group was removed with piperidine (wash 3), and the deprotected peptide 
eluted in washes 6,7. The combined fractions were lyophilised to give an oil, which 
formed a white solid on trituration with ether. Although the quality of the eluted 
peptide was reasonably good (Fig 2.13), the recovery of material was lower than 
might have been expected. The two small satellite peaks present were separated by 
HPLC and shown by FAB-MS to be methionine sulphoxide peptides, formed by 
aerial oxidation of the two methionine residues.
o 5 10 15 20  25 30  0
tim e (min)
5 10 15 20  25 30
tim e (min)
(a) Crude Tbfmoc peptide (b) After PGC purification
Figure 2.13: HPLC profiles of hGRP
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Other similar experiments were carried out. These included application of the 
crude TFA cleavage mixture directly to the PGC column, when the peptide could be 
successfully bound while the scavengers and other impurities eluted. In all these 
trials, reasonably good quality material was obtained, but with variable recoveries 
(typically, 10 mg of crude peptide gave 1.5-2 mg of product). This was possibly due 
to two factors:
(a) poor solubility of hGRP in the piperidine solution used to remove the 
Tbfmoc group, and subsequently only partial dissolution of the peptide 
on aqueous CH3CN/0.5% TFA washes;
(b) incomplete removal of the Tbfmoc group.
The latter seemed unlikely as no further material was obtained after additional 
piperidine washes. However, the former was consistent with the relatively large 
volume required to elute the Tbfmoc-deprotected peptide from the PGC (ca. 200 ml 
on a 3 g column) and with solution studies, when a faint precipitate was noticed 
(previously assumed to be a the piperidine adduct of fulvene (73)).
It therefore seemed crucial for the success of the method to select a solvent 
system that would avoid precipitation during the deprotection step, although at this 
stage this problem remained unresolved (see section 2.6.10).
2.6.3 UV determination of the Tbfmoc group
R a p h y l  30 suggested that the extent of incorporation of the Tbfmoc label into 
a resin-bound peptide could be estimated by cleaving the Tbfmoc group from a small 
portion of the resin using 20% Et3N/DMF and examining the UV spectrum of this
solution. As indicated for hGRP in section 2.6.2, there was a considerable 
discrepancy between the Tbfmoc content estimated by this method and that inferred 
by analytical HPLC of the crude material. Closer examination of the UV spectra of
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such solutions showed considerable fluctuations in profile over periods of up to 2.5 
h, when the spectrum stabilised.
20% piperidine in DMF has been used in a similar context, for estimating the 
Fmoc group147. This was tried as an alternative, but showed poorer UV 
characteristics than the Et3N solutions. However, the UV profile in 20%
piperidine/dioxane remained constant over a period of 24 h. Various concentrations 
of Tbfmoc-Leu-OtBu were then prepared in this solvent and their UV spectra 
recorded. The absorption at 366 nm was used as the basis for a revised Tbfmoc 
loading test (Figure 2.14).
Concentration (pM))
Figure 2.14: UV absorbance at 366 nm of 
various concentrations of Tbfmoc-Leu-OtBu 
in 20% piperidine/dioxane
2.6.4 Direct incorporation of the Tbfmoc group into resin bound peptides
Although a number of Tbfmoc amino acid derivatives had been synthesised 
from amino acid t-butyl esters, it became clear that this generally poor yielding
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reaction would render the synthesis of all suitably protected 20 amino acids a 
difficult and laborious task. As outlined earlier, it would be more efficient and 
convenient if an activated Tbfmoc derivative could be used to introduce the group 
directly onto the Na -terminus of the resin-bound peptide. This possibility was now 
investigated in some detail using a simple pentapeptide, Leu.Ile.Phe.Ala.Gly-Resin, 
'as a model system. At this time a reliable UV monitoring method had not been 
established and the incorporation of the Tbfmoc label was monitored by HPLC of 
the crude cleaved product (95% TFA/water).
Initial trials with p-nitrophenyl carbonate (72), using several equivalents in 
various solvents (DCM, dioxane, DMF) were unsuccessful, confirming earlier work 
reported by Raphy130. Carbonate (72) was therefore rejected and attempts were 
made to synthesise an alternative reagent, 17-tetrabenzo[a,c,g,i]fluorenylmethyl 
pentafluorophenyl carbonate (85).
Pentafluorophenyl chloroformate was generated in situ by treating 
pentafluorophenol in DCM with triphosgene in the presence of N,N-dimethylaniline. 
The reaction was monitored by IR and after 30 minutes the triphosgene carbonate 
peak at 1820 cm-1 had been replaced by a peak at 1810 cm '1. Alcohol (56) was then 
added to the solution along with one equivalent of N,N-dimethylaniline and the 
mixture stirred for several days, when a new carbonyl peak at 1775 cm' 1 was 
evident. The product was isolated by chromatography and the presence of Tbfmoc- 













However, neither the nor 13C NMR spectra were consistent with the 
expected Tbfmoc-OPfp structure (85). 13C NMR showed two carbonyl signals at
150.8 and 150.4 ppm and two CH2 signals at 75.4 and 73.2 ppm A high resolution
*H NMR spectrum resolved a three proton multiplet around 5 ppm into two distinct 
triplets at 5.12 and 5.08 ppm (integral ratio 2:1) and two distinct doublets at 4.82 and 
4.74 ppm (integral ratio 2:1). This suggested that the compound was in fact a 2:1 
mixture of two similar substances. Although TLC in several systems showed only 
one spot, the presence of two components was confirmed by HPLC (5 Jim silica, 
A=n-hexane, B=DCM, linear gradient of 0-50% B over 30 min., monitoring at 254 
nm), when two peaks were observed (Figure 2.15).
Figure 2.15 Analytical HPLC of 
isolated Tbfmoc-OPfp (85)
A comparison of the !H and 13C NMR shifts with an authentic spectrum of 
Tbfmoc chloroformate130 (70) suggested that this was^minor component present. 
This was confirmed by C, H and Cl microanalyses which were all consistent with a 
2:1 mixture of pentafluorophenyl carbonate (85) and chloroformate (70) (Table 2.2).
This was a rather surprising result as the chloroformate had previously been 
reported to be unstable. It also raised the question of how the chloroformate had been 
formed, since prior to addition of alcohol (56) to the reaction mixture no unreacted 








2:1 mixture of 
(37) & (23), 
%
c 74.9 73.3 81.1 75.4
H 3.58 3.14 4.14 3.41
Cl 1.82 _ 7.74 2.12
Table 2.2: Elemental analysis results for 
isolated Tbfmoc-OPfp (85)
The choroformate could have been formed if elimination of 






This seems unlikely on the basis of leaving group abilities but might become more 
favoured if the intermediate is sterically crowded.
However, the most likely explanation would seem to be from residual species 
such as (87), which could conceivably be formed during the reaction148.
Cl
o=c'
At this stage, since both components of the mixture could effect the desired 
reaction (incorporation of the Tbfmoc group) it was expedient to use this crude 
product for coupling trials with resin-bound pentapeptide, Leu-Ile-Phe-Ala-Gly. 
Encouragingly, ca. 50% incorporation of the Tbfmoc group was accomplished by 
sonicating with a 3-fold excess of reagent in either DCM or dioxane. DMF was also 
tried with moderate success but proved unsuitable due to the limited stability of 
Tbfmoc derivatives in this solvent.
Improved results were obtained by carrying out the reaction in the presence 
of a mild tertiary base (N,N-dimethylaniline) but virtually quantitative reaction was 
achieved using DCM as solvent in the presence of diisopropylethylamine as tertiary 
base. The generality of this procedure was demonstrated with a number of other 
resin-bound peptides that were available in this laboratory149' 152 (Table 2.3).
In the case of gastrin releasing peptide, the HPLC profile and FAB-MS of the 
material cleaved from the resin was compared with that obtained when the Tbfmoc 
group had been introduced by using Tbfmoc-Val-OH as the final amino acid. No 
significant differences were noted.
The other peptides shown in the table were used for further study (see 
sections 2.6.7-2.6.11). Tbfmoc peptide (88) proved to be unsuitable since the free
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cysteine thiol group, liberated by removal of the trityl group during the TFA 
cleavage, showed a tendency to dimerise when the peptide was treated with base to 
remove of the Tbfmoc group.





u (88)149 19 Cys(Trt) ca. I00%b
Hepatitis B, surface 
antigen, PreSl (1-23) avw 
(89)150
23 Met ca. I00%b
Gastrin releasing peptide 
(84)
27 Val ca. \00%b
Ubiquitin Y59F (90)151 76 Met 85%c




Phe-Leu-Phe-OH; ^HPLC; cmodified UV method (section2.7.3)
Table 2.3: Tbfmoc peptides synthesised
2.6.5 Synthesis of Tbfmoc-OPfp (85) and Tbfmoc-Cl (70)
Although a general method had now been developed for the introduction of 
the Tbfmoc group onto the N-termini of resin-bound peptides, the reagent so far used 
to accomplish this was a 2:1 mixture of chloroformate (70) and pentafluorophenyl 
carbonate (85). As indicated above, TLC in various systems showed no separation of 
the two components of the mixture. Recrystallisation also gave no separation.
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Although both components could in principle accomplish the same task, presumably 
one would react with peptide N-termini more efficiently than the other. To 
investigate this, pure samples of each compound were obtained by alternative routes.
Tbfmoc-OPfp (85) was prepared from dipentafluorophenyl carbonate1̂  in a 
reasonable yield:
OII
Low stability to base had previously been attributed to Tbfmoc-Cl130 (70)
and an earlier synthesis of this molecule proceeded via the TMS ether of 17-
tetrabenzo[a,c,g,/]fluorenylmethanol (56), giving a poor overall yield (18%). The
alternative and more direct route to (70) would be to simply react alcohol (56) with
phosgene or a phosgene substitute.
Equimolar amounts of alcohol (56) and N,N-dimethylaniline were therefore
taken in DCM with one third of an equivalent of triphosgene. Although with longer
reaction times (> 2-3 h), TLC showed significant decomposition of the product to
\
fulvene (73), if the reaction was quenched with water and acidfied with 2M HC1 
after 2 h then the chloroform ate could be obtained in a moderate yield of 49%.
Even better results were obtained if an excess of triphosgene was used (2/3 
equivalents) when the product precipitated out of the reaction mixture and could be 
isolated in good yield:
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(56) (70)
The relative reactivities of Tbfmoc-OPfp (56) and Tbfmoc-Cl (70) were then 
investigated.
2.6.6 Comparison of reactivities of Tbfmoc-OPfp (85) and Tbfmoc-Cl (70) with 
resin-bound peptides
Initial comparisons were carried out on resin-bound Leu-Ile-Phe-Ala-Gly, 
using three equivalents of each activated species in the presence of three equivalents 
of diisopropylethylamine. Tbfmoc incorporation was estimated using the modified 
UV method (section 2.6.3). The results are summarised in Table 2.4.
Reaaent Time Tbfmoc
incorporation
Tbfmoc-Cl 1 h ca. 100%




Table 2.4: Com parison of reactivities of 
Tbfmoc-CI and Tbfm oc-O Pfp
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Clearly, both reagents give the desired reaction with the resin-bound peptide, 
but the chloroformate (70) reacts much more quickly than the pentafluorphenyl 
carbonate (85). In fact, further studies showed the reaction with the chloroformate 
(85) to be complete in less than 30 min. This contrasts markedly with earlier 
reports130 which suggested that the chloroformate (70) gave only low coupling 
efficiences with resin-bound peptides. It was also found that the tertiary base was 
only necessary for Tbfmoc-Cl (70), to neutralise the liberated HC1. Similar results 
could be obtained for Tbfmoc-OPfp (85) without the addition of any base.
As a further comparison, the relative reactivities of the two species with a 
hindered peptide N-terminus (peptide (88), N-terminus Cys(Trt)), were investigated. 
Again quantitative incorporation was obtained with Tbfmoc-Cl (70), but only poor 
yields were obtained using Tbfmoc-OPfp (85) (14%) although this could be 
increased to 36% in the presence of diisopropylethylamine.
2.6.7 Hepatitis B surface antigen PreSl (1-23) avw:
Met-Gly-Gln-Asn-Leu-Ser-Thr-Ser-Asn-Pro-Leu-Gly-Phe-Phe-Pro-Asp-His- 
Gln-Leu-Asp-Pro-Ala-Phe-OH150 (89)
In contrast to hGRP, this acidic peptide was shown to be freely soluble in 70% 
aqueous CH3CN/1% piperidine and therefore the peptide was expected to show
much better elution properties on PGC after removal of the Tbfmoc group.
The Tbfmoc-peptide was cleaved from the resin with TFA/scavengers. A 
sample of the crude peptide was taken in 70 % aqueous CH3CN and applied to a
PGC column (particle size 50-100 (im). The Tbfmoc group was removed and the 
peptide eluted with 70% aqueous CH3CN/1% piperidine. The combined fractions
were neutralised with acetic acid, diluted, desalted and lyophilised to give a good 
crop of pure peptide (Fig 2.16).
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(a) Crude Tbfmoc peptide (b) After PGC purification
Figure 2.16: HPLC profiles of Pre SI (1-23) avw
2.6.8 Tbfmoc deprotection studies on PGC
Encouraged by this result, Tbfmoc-peptide (89) seemed an ideal system with 
which to investigate and optimise the deprotection of the Tbfmoc group on PGC. In 
a typical experiment, 1.5 mg of Tbfmoc-peptide was taken in 5 ml 70% aqueous 
CH3CN and 120 mg of PGC (particle size 50-100 pm) added. The adsorption of the
Tbfmoc peptide from the solution was monitored by the UV absorbance at 350-400 
nm. The supernatant liquor was then pipetted off and 5 ml of the deprotection 
solution added. Samples of the basic solution were taken periodically, and after 
neutralising with acetic acid the release of the peptide from the PGC was monitored 
by HPLC. The results are summarised in Table 2.5.
These figures should be compared with Tbfmoc deprotection in solution which 
is usually complete in 1 minute using 1% piperidine solutions. Clearly, the
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deprotection is greatly retarded when the peptide has been adsorbed onto PGC. The 
possibility that this was merely reflecting slow diffusion of the deprotected peptide 
from the surface of the carbon was discounted by quenching a 1% piperidine/ 
aqueous 70% CH3CN suspension of the peptide on PGC with acetic acid after 5
minutes, after which no further liberation of the peptide was observed.
Deprotection solution Deprotection Time
1% piperidine/70% aq. 
CH3CN
60 min
10% piperidine/70% aq. 
CH3CN
10 min
1% piperidine/70% aq. 
CH3CN/2.6 M urea
30 min
1% piperidine/50% aq. 
CH3CN/1.5M Gdm.HCl
60 min
5% piperidine/50% aq. 
CH3CN/1.5M Gdm.HCl
20 min
10% pyrrolidine/70% aq. 
CH3CN
10 min




^extensive peptide degradation noted after 10 min.
Table 2.5: Deprotection of Tbfmoc group 
from peptide (89) adsorbed onto PGC
This lower deprotection rate on PGC is probably due to the acidic hydrogen 
(H-17) being shielded by the carbon surface from basic attack. In any case, this study 
showed that a piperidine concentration of 10% is necessary for reasonably fast 
deprotection of the Tbfmoc group on PGC.
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2.6.9 Comparison of different grades of PGC for adsorption of peptides
Up until this time, large particulate PGC (particle size 50-100 pm) had been 
used. A comparison was made between this material and HPLC grade PGC (particle 
size 7 pm). PGC was added to solutions of Tbfmoc-peptide (89) (1.5 mg in 5 ml of 
70% aqueous CH3CN) and the adsorption of the peptide onto the surface of the
carbon monitored by the UV absorbance of the supernatant liquor at 350-400 nm:
The smaller mass of HPLC grade PGC required at least partially reflects the larger 
surface area of this material (175-200 m2/g, compared with 68 m2/g), but other 
factors may be involved. For instance, the larger particulate material had been used 
in previous experiments and not all of the surface activity may have been restored on 
washing with hot dioxane130.
In light of this finding, however, further peptide purifications were carried out 
using HPLC grade material, with the carbon being added to the peptide solution and 
the supernatant liquor removed after centrifugation.






PGC particle size 
50-100 pm 
7 pm




This peptide is an 85 amino acid section of a larger protein which binds to 
methylated DNA154. It has recently been synthesised in this laboratory152 and was 
thought to provide a good test of the Tbfmoc/PGC methodology, especially as it, like 
hGRP, proved to be insoluble in aqueous CE^CN/piperidine solutions.
The Tbfmoc-peptide was cleaved from the resin with TFA/scavengers. As the 
Tbfmoc peptide represented a relatively small amount of the crude material (Fig 
2.17) any losses due to precipitation on the PGC would not be tolerated. A solvent 
system that would prevent precipitation of the peptide at alkaline pH was therefore 
sought.
It was thought that addition of chaotropic agents, such as guanidinium 
hydrochloride (Gdm.HCl) or urea might prove useful, since these are frequently used 
as solubilising agents for peptides and proteins. To facilitate this study, a small 
amount of the Tbfmoc peptide was isolated in solution by preparative HPLC. HPLC 
grade PGC was then added to samples of the eluent to adsorb the Tbfmoc peptide. 
The supernatant liquor was removed, a deprotection solution added and any release 
of the peptide from the PGC monitored by HPLC. 10% piperidine in 50% aqueous 
CH3CN/1.5M Gdm.HCl failed to elute the peptide, but increasing the Gdm.HCl
concentration to 3M eluted some product. 10% Piperidine in 50% aqueous 
CH3CN/4M urea also proved reasonably successful. However, best results were
obtained using 10% piperidine in 50% aqueous isopropanol, a solvent system which 
has the advantage of being completely volatile.
Having found a suitable solvent system a sample of the crude Tbfmoc peptide 
was taken in 2.5 % acetic acid/50% aqueous isopropanol. HPLC grade PGC was 
added to adsorb the Tbfmoc peptide then the solution centrifuged and the supernatant 
pipetted off. The carbon was then subjected to the following washing protocol:
1. 2.5% acetic acid/50% aqueous isopropanol (5 ml)
2. 50% aqueous isopropanol (5 ml)
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3. Tbfmoc deprotection: 10% piperidine/50% aqueous 
isopropanol (2 ml), wait 10 min
4. 50% aqueous isopropanol (2 ml)
5. 10% piperidine/50% aqueous isopropanol (2 ml)
6. 50% aqueous isopropanol (5 ml)
Washes 3, 4, 5, and 6 were combined and the solvent removed in vacuo. The peptide 
obtained was of reasonable purity (Fig 2.17), but was subjected to a final purification 
by HPLC to give single peak material.
tim e (min)
(a) Crude Tbfmoc peptide
10 15 20
tim e (min)
(b) After PGC purification (c) After preparative HPLC
Figure 2.17: HPLC profiles of MeCP2 
Methylated DNA Binding Domain (91)
Recent experience suggests that the solvent system used here should be 
applicable to a wide range of peptides. For instance, much better recoveries of hGRP 
(section 2.6.2) were obtained when the acetonitrile based solvent system was 
replaced with an aqueous isopropanol system.
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2.6.11. Tbfmoc as a hydrophobic group for purification of peptides by RP- 






The hydrophobic nature of the Tbfmoc group markedly increases the RP- 
HPLC retention times of peptides to which it is attached. This property can also be 
used for purification of peptides, and is facilitated by the fact that the Tbfmoc 
peptide can be readily identified by its UV absorption at 364 nm.
This proved useful for the purification of ubiquitin analogue UbY59F151, a 
76-amino acid protein. The crude peptide was shown to contain two major 
components, in almost 1:1 ratio. In the absence of the Tbfmoc group these eluted 
almost coincidentally on HPLC, making purification and characterisation of the 
components difficult. When the Tbfmoc group was introduced onto the resin-bound 
peptide and the peptide cleaved from the resin, these two components, FI and F2, 
were shown to be labelled with the Tbfmoc group (Fig 2.18a).
However, in the presence of the Tbfmoc-label the two components became 
easily separable by preparative HPLC. Removal of the Tbfmoc group and further 
preparative HPLC gave the two peptides in pure form (Fig 2.18b, c). 
Characterisation by amino acid analysis and laser-desorption mass spectrometry 
(Figure 2.19) showed the later-eluting peptide, F2 to be the required sequence, whilst 
the earlier-eluting peptide, FI was the desired peptide with an oxidised methionine. 
This was further confirmed by oxidation-reduction studies when the two species 
could be interconverted1
This seems to indicate that the Tbfmoc-group may have some potential for 
enhancing the HPLC separation of even very similar sequences (e.g. where a residue
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(a) Crude Tbfmoc peptide
(b) Purified FI (c) Purified F2
Figure 2.18: HPLC profiles of Ubiquitin analogue, UbY59F
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Figure 2.19: Laser desorption mass spectra of peptides FI and 
F2 (instrument calibrated with bovine ubiquitin, a  ± 5.2 Da)
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has been modified by a side reaction during cleavage), although the large separation 
encountered in the above case was almost certainly due to the proximity of the 
Tbfmoc group to the N-terminal methionine that had been oxidised.
2.7 Concluding remarks
The Tbfmoc group has proved to be an effective affinity label for the 
purification of peptides up to 85 amino acids in length on PGC or by RP-HPLC. 
This method has shown wide applicability and in addition to the peptides discussed 
has been used in this laboratory for the purification of bacteriophage X restriction 
alleviation (RAL) peptide156 (66 residues) and for a range of ubiquitin analogues157 
(76 amino acids).
The upper limit, in terms of peptide size, at which this methodology will 
cease to be effective has not been reached during these studies. Preliminary trials 
with synthetic lysozyme (129 residues) have shown that the affinity of the Tbfmoc- 
peptide for PGC remains strong and that it will be useful to effect at least a 
preliminary purification.
In the future this methodology should allow other large synthetic peptides to 
become more readily accessible while the stability of PGC to TFA/scavengers offers 
the potential of directly adsorbing the crude Tbfmoc cleavage mixture onto carbon. 
This opens up the possibility of a completely automated peptide synthesiser, 




SYNTHESIS OF C-TERMINAL 
PEPTIDE DERIVATIVES
3.1 Design of a linker for SPPS
A suitable linker for SPPS must form a relatively stable carbocation to
facilitate cleavage of the the peptide by an SN1 mechanism on acid treatment:
Peptide— [Linker]----(p )  -----i l --------- » .  Peptide + + [Linker]---- (p )
Pless158 has studied the relative stabilities of various benzhydryl carbocations 
(Table 3.1). Based upon these findings and the estimated carbocation-stabilising 
effect of an alkoxy substituent1̂ ,  McInnes1®1 reasoned that that an 
alkoxydibenzocycloheptadiene system would form the basis of a linker, suitable for 
SPPS, from which the peptide could be released on mild acidolysis.
Linkers (92) and (93) were subsequently developed for the synthesis of 
peptide C-terminal amides and hydrazides, when the peptide could be liberated from 
the resin on treatment with dilute TFA.
X
OCHj- (?)
^CL)X= —  NHFmoc
(T3 )X =  —  NHNHBoc
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k j  k J
-14.0
R+ + H20  —-------- ROH + H+
Table 3.1: Relative carbocation stabilities158
3.2 Synthesis of 2-hydroxydibenzocycloheptadien-5-one (100)
In the synthesis of linkers (92) and (93), 2-hydroxydibenzocycloheptadien-5- 
one (100) is a key intermediate. The route to this molecule developed by McInnes160 
is shown in figure 3.1 and, although a good overall yield of 38% was achieved, two 
of the intermediates were oils and three steps involved chromatographic separations. 
To facilitate large scale synthesis of the linker some modifications were nec-essary.
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C02Me
NBS, dibenzoyl peroxide C 02Me



























Figure 3.1: McInnes synthesis of 
2-hydroxydibenzocycloheptadien-5-one (100)160
In the Wittig reaction (Fig 3.1, step C) removal of the triphenylphosphine 
oxide by-product had proved troublesome1̂ .  Initial attempts to circumvent this 
problem using the Horner-Emmons procedure, where water-soluble by-products are 
formed, were unsuccessful. Instead, by immediately hydrolysing the crude stilbene 
ester product (96) then the triphenylphosphine oxide by-product could be easily 
removed on aqueous work up of the resulting acid (101) (Figure 3.2). The procedure
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was further refined by using l,8-diazabicyclo[5.4.0]undecene-5 (DBU) as the base 
for the Wittig reaction, when reaction proceeded smoothly in dioxane at 50°C.
Reduction of (101) proceeded almost quantitatively and attempts were then 
made to effect a one-pot cyclisation to the dibenzocycloheptadiene system, with 
concomitant cleavage of the methyl ether.
The acid chloride of (101) was generated in situ with oxalyl chloride161 and 
treated with a mild Lewis acid, tin (IV) chloride. Only the cyclisation reaction was 
observed, the ether group remained injact.
^ ^ c ° 2h  SnCl4
11 x L  Benzene
^  OMe
(98)
However, a stronger Lewis acid, aluminium chloride, effected both of the desired 
reactions in high yield to give the linker precursor (100).
This modified synthesis (Figure 3.2) proved highly successful in enabling 
large quantities of the linker precursor to be obtained in an increased overall yield of 
52% and without recourse to chromatographic purification. No problems were 
encountered on scaling up the reactions and each step has been carried out on at least 
























Figure 3.2: Modified synthesis of 
2-hydroxydibenzocycloheptadien-5-one
3.3 Attachment of the linker to polystyrene resin
In the initial report16̂ ’ the linker was loaded onto polystyrene resin by a 





Although this reaction resulted in quantitative incorporation of the linker moiety, this 
is not always advantageous. In the synthesis of long peptides it is preferable to keep 
the level of substitution relatively low to reduce inter-chain aggregation which can 
drastically reduce coupling yields. Furthermore the ability to cap unreacted sites on 
the resin is desirable to prevent any unwanted attachment of amino acids and 
subsequent chain assembly during synthesis. Neither of these requirements is easily 
fulfilled by anchoring the linker to chloromethylpolystyrene resin. Therefore, the 




Acid (104) was then activated as a diphenylphosphinic mixed anhydride67 
(105) and reacted with an aminomethylpolystyrene resin. This reaction proceeded 










This quick and efficient reaction should enable the loading of the linker to be 
readily controlled by the amount of mixed anhydride used. Unreacted aminomethyl 
groups can then be capped with acetic anhydride using standard cycles on an 
automated peptide synthesiser.
The ketone group of (106) was reduced with lithium borohydride and the 
alcohol (107) so obtained used to derivatise the resin with protected hydrazine and 
amine functionalities by reaction with BocNHNH2 and FmocNH2, respectively
(Figure 3.3). These reactions were analogous to those carried out by McInnes160 on 
the linker anchored to Merrifield resin and employed similar reaction conditions.
O OH
(109)
Figure 3.3: Synthesis of amide 
and hydrazide linkers
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To compare the properties of the linker attached to both Merrifield resin and 
to aminomethyl resin, bombesin162, a peptide C-terminal amide, was synthesised 
using resins (92) and (108).
Bombesin:
Glp-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2
The yields of crude peptide cleaved from the resin were 74% and 97% 
respectively. This seems to indicate the superiority of resin (108), with the linker 
anchored to aminomethyl polystyrene resin. However, these figures should be treated 
with caution since the peptides could vary in the quantity of residual scavengers 
associated with them and in the extent of removal of TFA from the crude cleavage 
mixture, which would affect the ether precipitation of the peptide.
3.4 Synthesis of a peptide amide: Bombesin
5 10 15
tim e (min)
20 5 10 15
time (min)
20
(a) Synthesised with resin (92) (b) Synthesised with resin (108)
Figure 3.4: HPLC profdes of crude bombesin
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HPLC traces of the crude peptides are shown in Figure 3.4. Although there 
are slight differences, in each case the major peak correpdonded to the required 
peptide and from this limited comparison it would seem that both resins can be used 
effectively for the synthesis of peptide amides. However, resin (108) seems to be 
preferable on the basis of the amount of crude product obtained. Furthermore, this 
resin has other intrinsic features that make it more attractive than resin (92). For 
instance, the linker molecule could conceivably be released from the resin during 
cleavage, with undesirable consequences. This could occur by the mechanism shown 
in Figure 3.6, when expulsion of the linker moiety would form a relatively stable 
benzyl cation on the resin. The reactive dienone released could then react with the 
peptide if not efficiently scavenged. Any tendency for this to occur would be 
suppressed using resin (108) where the amide spacer prevents the formation of a 
benzyl cation.
Peptide:' Peptide
Figure 3.5: Possible release of the linker moiety 
from the resin during cleavage
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McInnes160 attempted to synthesise peptide acids using resin (110), by 




3.5 Synthesis of peptide C-terminal acids
OH O
(110)
However, when the synthesis of a hexapeptide was carried out using standard double 
couple cycles (symmetrical anhydride then HOBt ester couplings), only half of the 
expected peptide remained on the resin at the end of the synthesis. This was 
attributed to the use of the acidic HOBt coupling agent, which cleaved the peptide- 
linker ester bond.
Resin (107) contains an electron-withdrawing amide group, which might 
exert a minor effect on a the acid stability of a peptide bound to the linker as an 
ester. This was investigated by coupling Fmoc-Gly-OH to the resin as a symmetrical 




Resin (111) was sonicated in a solution of HOBt/DMF. Samples of the resin were 
taken periodically and the quantity of amino acid on the resin estimated by the Fmoc
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UV loading test147. As a control, the same experiment was carried out on the Wang 
linker loaded with Fmoc-Gly-OH, when the amino acid-resin linkage proved stable 
over a period of 24 h.
The results are shown in Figure 3.6, and clearly the amino acid-resin bond 
has low stability to HOBt, rendering the synthesis of peptide C-terminal acids 
impractical using standard methodology.
Time (ruin)
Figure 3.6: Stabilty of resin (111) to HOBt (0.5 M/DMF)
3.6 Synthesis of peptide C-terminal secondary amides
Despite the fact that many biological receptors are activated by peptides, 
peptides in general are not attractive drug candidates. One of the main reasons for 
this is the widespread occurrence of proteolytic enzymes in the body, leading to short 
lifetimes of administered peptides. Futhermore peptides are highly polar and poorly 
soluble in organic solvents hence will not pass through lipid membranes unless 
actively transported. It might therefore be desirable to incorporate a feature into a
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peptide molecule that will enhance lipid solubility. A number of recent studies163’164 
have focused on lypophilic modifications to enhance transport of peptidic molecules 
into the central nervous system, e.g. cholesteryl ester derivatives of Leu- 
enkephalin164.
Attempts were made to modify the dibenzocycloheptadiene linker to allow
the routine synthesis of peptide C-terminal secondary amides, (peptide-NH-R, where
R is a long chain alkyl group), without recourse to nucleophilic cleavage, which has
previously been used to obtain such molecules93.
R=n-heptyl was selected as a model system. Initial attempts to introduce the
amine onto the 5-position of the linker employed an acid catalysed reaction with
hydroxy resin (110) in an analogous fashion to the reaction used to introduce Fmoc- 
NH2 onto the resin. However, no incorporation was achieved either with the free
amine or with Fmoc-protected heptylamine:
McInnes160 had previously shown the ketone of alkoxy ketones such as (102) 
to be of rather low reactivity, failing to undergo either a Leuckart reaction or oxime 
formation This is presumably due to the vinylogous ester nature of the molecule. 
However, the ketone function of resin (102) was found to react with heptylamine in 








The reaction was monitored by IR, which showed the gradual disappearance of the 
ketone band at 1640 cm-1 over a period of 2.5 h. Virtually quantitative incorporation 
of the heptylamine was confirmed by nitrogen analysis. It was not possible to 
confirm the imine structure of the resin (112) and this structure was assigned on the 
basis of analogous reactions in the literature165.
Imine (112) was reduced to the secondary amine (113) using lithium 
borohydride and this reaction was judged to be successful by the appearance of a 





An amino acid was then coupled to the resin. Glycine was activated as its 
acid chloride and reacted with the resin-bound amine. After 2 h an Fmoc loading 
test147 indicated a coupling efficiency of 40%. Higher loadings could be achieved 
with more extended reaction times, however some discolouration of the resin was 
noted.
This resin (114) was used to synthesise a pentapeptide N-heptyl amide, Leu- 
Ile-Phe-Ala-Gly-NH-(CH2)CH3 (115). The peptide was liberated from the resin in
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TFA, using anisole and water as carbocation scavengers. The presence of the 
required peptide was confirmed by amino acid analysis and accurate FAB-MS. The 
enhanced lypophilic nature of the peptide was apparent from the enhanced retention 
time on RP-HPLC and the peptide's reluctance to precipitate from the crude cleavage 
mixture after stripping the mixture of TFA and adding ether. The peptide was finally 
obtained in solid form by partitioning between pet. ether (40-60) and water.
Attempts were then made to introduce amino acids other than glycine. 
Leucine symmetrical anhydride was generated using DIC and reacted with resin 
(113) in 1:1 DMF/dioxane. The reaction was monitored by Fmoc loading tests147 on 
small aliquots of resin. The reaction proceeded rather sluggishly, but after sonicating 
the mixture overnight then adding fresh symmetrical anhydride and sonicating for a 
further period, sufficient incorporation of the the amino acid was achieved, although 








The N-heptylamide derivative of Leu-enkephalin (117) was then synthesised 
using resin (117), giving the peptide in an overall yield of 55% after cleavage from 
the resin and purification by semi-preparative HPLC.
Although the utility of this resin has been demonstrated in principle, for 
future use quicker and more efficient coupling of the first amino acid would be 
desirable. With such long extended symmetrical anhydride couplings racemisation 
could be a risk. In this respect, the PyBroP coupling agent has beer, recently 
reported87 to give efficient coupling of N-methyl amino acids and might prove 
useful for coupling the first amino acid to this secondary amine resin.
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Aza-amino acids have previously been incorporated into peptides as non­
3.7 Synthesis of C-terminal aza-glycine peptides
led to the development of numerous peptides of actual or potential therapeutic use. 
For instance, potent LHRH antagonists167 and agonists161* containing a C-terminal 
aza-glycine amide have been synthesised, the latter of which has proved valuable as 
a drug (Zoladex) for the treatment of prostate cancer.
Although C-terminal aza-amino acids would seem useful moieties to be 
routinely incorporated into peptides for biological studies, only one linker suitable 
for the solid phase synthesis of such species has been proposed167.
The amine resin (108) was therefore modified for this use by removal of the 
Fmoc group with 20% piperidine in DMF, then treating the liberated amine with 
triphosgene, to generate an isocyanate (118) in situ. This activated species was 
trapped with Fmoc-hydrazine, when an Fmoc loading test147 showed good 
incorporation of the hydrazine derivative, to form a resin-bound aza-glycine moiety











A small peptide Leu-Ile-Phe-Ala-azaGlyNH2 (120) was synthesised as a test 
sequence using resin (119). The peptide was cleaved from the resin with 95% 
TFA/water and analytical HPLC (Figure 3.6) showed one main product with two 
smaller but significant side products. These were separated by semi-preparative 
HPLC.
Amino acid analysis on each fraction showed the presence of the four 
required amino acids in equimolar ratios. Accurate mass FAB-MS showed the main 
component to be the required peptide, while the nominal FAB-MS of the early and 
late-eluting contaminants showed peaks at 477 and 462 respectively.
5 10 15 . 20  25  5 10  15 20  25
tim e (min) tim e (min)
(a) Crude (b) Purified
Figure 3.7: HPLC profiles of Leu-De-Phe-Ala-azaGlyNH2
The first product would appear to be Leu-ne-Phe-Ala-NH2 (MW 461),
formed by loss of urea from the target compound, while the second component could 
be hydrazide, Leu-Ile-Phe-Ala-NHNH2 (MW 476). Clearly further work is required
to establish the nature and extent of the side reactions that occur with this resin 
during cleavage. Nevertheless, the desired peptide was isolated in an overall yield of
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Amino acid derivatives were purchased from Aldrich, Sigma or 
Novabiochem and were used as supplied. Melting points were determined in open 
capillaries using a Biichi 510 melting point apparatus and are uncorrected. Thin layer 
chromatography (TLC) was performed with silica gel 60GF-254 (Merck 5735) on 
plastic or aluminium sheets in the following solvent systems:
A 30% ether/n-hexane 
B chloroform
C 10% methanol/chloroform 
D 1:1 dichloromethane/n-hexane 
E dichloromethane
F 9:1:0.5 chloroform/methanol/acetic acid 
G 30% dichloromethane/hexane 
H toluene
Compounds were visualised using suitable combinations of the following methods: 
iodine vapour, ultra-violet absorption at 254 and 352 nm, methanolic sulphuric acid, 
Mary's reagent (4,4'-6/s(dimethylamino)diphenylcarbinol and ninhydrin. Optical 
rotations were measured on an AA 1000 polarimeter using a 1 dm cell in the solvents 
quoted. Flash chromatography was performed using silica gel 60 230-400 mesh (wet 
flash) or silica gel 60H 5-40 (im (dry flash). HPLC was performed using Applied 
Biosystems equipment (2 x 1406A or 2x400 solvent delivery systems, a 1480A or 
491 injector mixer and a 783A programmer detector). The following columns and 
solvent gradients were used and in all cases A=0.1% aqueous TFA, B=CH3CN/0.1%
TFA, monitoring the eluent at 214 nm, unless stated.
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Column Specifications
A Aquapore Cjg, 220x4.6 mm, 7 p.m
B Aquapore Cjg, 100x4.6 mm, 7 |im
C Aquapore Cg, 100x4.6 mm, 7 (im
D Aquapore Cg, 250x10 mm, 7 (im
E Aquapore Cjg, 100x10 mm, 7 fim
F Aquapore C^g, 250x10 mm, 7 (im









1 10 50 1.00 30
2 10 90 10.00 45
3 10 40 10.00 45
4 10 90 1.00 30
5 20 75 1.00 30
6 10 90 10.00 30
7 10 90 5.00 45
8 10 90 1.00 20
9 10 60 5.00 45
10 10 90 10.00 45
Infrared spectra were recorded on either a Perkin-Elmer 781 or Bio-Rad FTS-7 
spectrophotometer in dichloromethane solution, as KBr discs or nujol mulls. 
Ultraviolet spectra were recorded on a Cary 210 spectrophotometer. Mass spectra 
were obtained using Kratos MS50TC, AEI MS-902, Kratos Kompact Maldi-TOF, 
and Finnegan Laser-Mat machines. Proton NMR spectra were recorded on either
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Briiker WP 80 (80 MHz), WP 200 (200 MHz) or WH (360 MHz) machines in the 
solvent indicated relative to a tetramethylsilane external standard. Carbon-13 NMR 
spectra were recorded on a Briiker WP 200 (50 MHz) or WH 360 (90 MHz) 
machines in the solvents indicated relative to tetramethylsilane as external standard. 
Fluorine-19 NMR spectra were recorded on a Briiker WP 80 (75 MHz). Elemental 
analyses were carried out on Carlo Erba 1106 or Perkin-Elmer 2400 instruments. 
Amino acid analysis was carried out on an LKB 4151 alpha plus amino acid analyser 
susequent to Carius tube hydrolysis with constant boiling hydrochloric acid at 
110°C. N,N-dimethylformamide and dioxane were peptide synthesis grade. Other 
solvents were of analytical grade or were distilled before use. The following solvents 
were dried when required using the reagents indicated: benzene (sodium wire), 
dichloromethane (calcium hydride), diethyl ether (sodium wire), THF 
(sodium/benzophenone indicator), toluene (sodium wire).
4.1,1 Elemental analyses on tetrabenzo[a,c,g,i]fluorene derivatives
In this and related studies130’142 microanalysis results on 
tetrabenzo[a,c,g,/]fluorene derivatives have proved generally unsatisfactory, giving 
lower carbon content than that calculated for the expected molecular formulae. This 
has been attributed to the large number of quaternary carbons present leading to poor 
combustion. Increased oxygen concentrations and the addition of vanadium 
pentoxide have given improved results (see Appendix for an example169) although 
these have still not proved entirely satisfactory and this is the subject of on-going 




9-Bromophenanthrene (20 g, 77.8 mmol) was taken in THF (40 ml) and slowly 
added to Mg turnings (2.0 g, 8.2 mmol) together with a crystal of iodine, in an 
atmosphere of dry nitrogen. The mixture was stirred for 1 h then ethyl formate (2.88 
g, 3.89 mmol) slowly added. After 1.5 h, ice (10 g) then aqueous NH4C1 (20 g in 40 
ml H2O) was added and a white solid precipitated on stirring. A further 40 ml of 
H20  was added, the precipitate filtered off and washed with water. The solid was
taken up in DCM and combined with a DCM extract of the aqueous filtrate. The 
solution was dried (MgS04) and solvent removed in vacuo. The residue was
triturated with ether to give a white solid (7.7 g, 52%).
m.p. 234-237°C; Found: C, 90.2; H 5.43. C29H20O requires C, 90.6; H, 5.20%; 
TLC: Rf (A) 0.23; SH(200 MHz, CDC13): 9.10 (2H, d, J=7.6 Hz, aromatic), 9.03
(2H, d J=8.3 Hz, aromatic), 8.46 (2H, d J=7.7 Hz, aromatic) 8.08-8.05 (4H, m, 
aromatic), 7.93-7.76 (8H, m, aromatic), 7.53 (1H, d J=6.0 Hz, CH), 5.08 (1H, d 
J=6.0 Hz, OH); vmax(Nujol): 3400 (OH), 1600 (aromatic C=C) cm-1; ^ ^ (D C M ):
298 (e 19700 d m W 'W 1), 286 (18900), 277 (24900), 255 nm (104000); m/z 
(El): 384 (M+), 366, 205, 178; HRMS: 384.1519, C29H20O requires 384.15141.
8Z>H-Tetrabenzo[a,c,g,i]fluorene (61)
(B/s-phenanthren-9-yl)methanol (5.2 g, 13.5 mmol) was taken in DCM (100 ml) and 
TFA (15 ml) added. The mixture was swirled for 2 min then the solvent removed in 
vacuo and the residue triturated with ether to give the product as a yellow solid 
(4.47 g, 90%).
m.p. 277-280°C; Found: C, 94.2; H, 5.07. C29 H 18 requires C, 95.1; H, 4.92%; TLC: 
Rf (A) 0.34; 8h(80 M H z , CDCI3): 8.82-8.75 (2H, m. aromatic), 8.30-7.08 (15H, m,
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aromatic & CH), 5.42 (1H, s, CH); vmax(Nujol): 1620 (aromatic C=C) cm"1; 
^ „ (D C M ): 376 (e 12600 dmSmoHcnr1), 360 (10600), 302 (34200), 290 (36200),
280 (39500), 256 nm (66800); m/z (El): 366 (M+), 365, 364, 363, 182; HRMS: 
366.1419, C32H24O3 requires 366.14084.
17-(MethoxycarbonyI)tetrabenzo[a,c,g,i]fluorene (64)
8bH-Tetrabenzo[a,c,g,z]fluorene (0.5 g, 1.37 mmol) was taken in THF (25 ml) under 
an atmosphere of dry nitrogen and cooled to -78°C. A solution of n-butyllithium in 
cyclohexane (1.6 M titrated, 0.93 ml, 1.48 mmol) was added and the deep orange- 
coloured mixture stirred at -78°C for 15 min. Methyl chloroformate (0.2 ml, 2.59 
mmol) was added and the mixture stirred at -78°C for 1 h then at room temperature 
for 30 min, when the orange colouration had faded significantly. The reaction was 
quenched with water and the organic layer extracted with DCM, dried (MgSC^) and
the solvent removed in vacuo. DCM (20 ml) was added to the residue, the insoluble 
solid filtered off and the solvent removed from the filtrate in vacuo. This was 
repeated, then the residue triturated with ether to give the title compound as a yellow 
solid (0.10 g, 16%)
m.p. 238-240°C; Found: C, 88.5; H, 4.89. C31 H20O2 requires C, 87.7; H, 4.72%; 
TLC:Rf (A) 0.23, Rf (H) 0.45; 5H(200 MHz, CDC13): 8.80-8.64 (6H, m, aromatic),
8.28-8.24 (2H, m, aromatic), 7.75-7.25 (8H, m, aromatic), 5.60 (1H, s, CH), 3.50 
(3H, s, OMe); vmax(DCM): 3080 (aromatic CH), 2960 (aliphatic CH), 1730 (ester 
C=0), 1610 (aromatic C=C), 1500, 1210, 1090 cn r1; ^ ( D C M ) :  370 (e 17000
dm3mol'1cm '1), 302 (42700), 290 (34700), 253 nm (66200); m/z (El): 424 (M+), 
364, 181; HRMS: 424.1474, C31H2o02 requires 424.14632.
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Ethyl 3-(17-tetrabenzo[a,c,g,i]fluorenyI)propanoate (65)
8£H-Tetrabenzo[a,c,g,/]fluorene (0.2 g, 0.546 mmol) was taken in THF (10 ml) 
under an atmosphere of dry nitrogen and cooled to -84°C. A solution of n- 
butyllithium in cyclohexane (1.61 M titrated, 0.40 ml, 0.640 mmol) was added and 
the deep orange-coloured mixture stirred at -84°C for 25 min. Ethyl acrylate (0.10 
ml, 0.924 mmol) was added and the mixture stirred at -84°C for 30 min then at room 
temperature for 1 h. The solvent was removed in vacuo and the residue purified by 
dry flash chromatography using DCM as eluent. Appropriate fractions were 
combined and the solvent removed in vacuo. The residue was taken up in ether and 
the ether allowed to slowly evaporate to leave the title compound as a pale yellow 
solid (0.079 g, 31%).
m.p. 181-182°C; Found: C, 87.2; H 5.84. C34H2602 requires C, 87.6; H, 5.84%; 
TLC: Rf (A) 0.24; 8H(200 MHz, CDC13): 8.83-8.65 (6H, m, aromatic), 8.28-8.23
(2H, m, aromatic), 7.75-7.58 (8H, m, aromatic), 5.09 (1H, t J=4.4 Hz, CH), 3.58 
(2H, q J=7.1 Hz, OCH2), 3.04-2.94 (2H, m, CH2), 1.39-1.31 (2H, m, CH2), 0.84 
(3H, t J -  7.1 Hz); vmax(DCM): 3080 (aromatic CH), 2995 (aliphatic CH), 1730 
(ester C=0), 1610, 1500, 1380, 1215, 1175 cm’1; ^ ( D C M ) :  380 (e 12000
dm^moHcnr1), 365 (12800), 302 (28300), 289 (23600), 254 nm (48300); m/z (El): 
466 (M+), 424, 364, 363, 182; HRMS: 466.1926, C34H260 2 requires 466.19327.
Tetrabenzo[a,c,g,i]fluoren-17-one (63)
86H-Tetrabenzo[a,c,g,/]fluorene (0.3 g, 0.819 mmol) was taken in THF (20 ml) and 
sodium methoxide (0.22 g, 4.07 mmol) added. The mixture was stirred for 15 min 
then poured into water (100 ml), acidified to pHl with concentrated hydrochloric 
acid and extracted with DCM (3 x 50 ml). The extract was dried (MgS04) and the
solvent removed in vacuo to give the title compound as dark needles (0.21 g, 67%).
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m.p. 302-305°C (lit133 295°C); Found: C, 89.9; H 4.22. C29H160  requires C, 91.6; 
H, 4.21%; 5h (200 MHz, CDC13): 9.23-9.18 (2H, m, aromatic), 8.78-8.63 (4H, m,
aromatic), 8.28 (2H, dd J=8.2 Hz, 1.7 Hz, aromatic), 7.83-7.60 (8H, m, aromatic); 
TLC: Rf (A) 0.34; vmax(DCM): 1695 (C=0), 1605 (aromatic C=C), 1505 cm '1;
^ „ (D C M ): 425 (e 2000 dm3mol-1cm-1), 336 (37100), 320 (31400), 253 nm
(78100); m/z (FAB): 381 (MH+), 380 (M+); HRMS: 380.12015, C29H160  requires
380.12011.
Tetrabenzo[a,c,g,i]fluorene (52)
86H-Tetrabenzo[a,c,g,/]fluorene (0.5 g) was taken in THF (40 ml) and 3 drops of 
triethylamine added. The solution was mixed for 1 min, then the solvent removed in 
vacuo. Ether was added to the residue to give the title comound as a yellow solid 
(0.45 g, 90%).
m.p. 281-283°C (lit133 275-276°C); Found: C, 95.6; H 4.94. C29H 18 requires C, 
95.1; H, 4.92%; TLC: Rf (A) 0.48; 5H(200 MHz, CDC13): 8.83-8.68 (6H, m,
aromatic), 8.23-8.18 (2H, m, aromatic), 7.74-7.58 (8H, m, aromatic), 4.62 (2H, s, 
CH2); vmax(Nujol): 1610 (aromatic C=C), 1500 cm'1; ^ ( D C M ) :  378 (e 16500
dm3mol‘1cm"1), 364 (17600), 301 (39600), 288 (33300), 261 (61500), 254 nm 
(65600); m/z (FAB): 366 (M+), 324; HRMS: 366.14987, C29H 18 requires
366.14084.
Ethyl (6i's-phenanthren-9-yl)glycolate (54)
9-Bromophenanthrene (100 g, 0.389 mol) was dissolved in dry THF (200 ml) and 
slowly added to Mg turnings (10 g, 0.41 mol), together with a crystal of iodine under 
an atmosphere of dry nitrogen. After initiation of the reaction, the mixture was 
cooled on an ice-bath to control the initial vigour of the reaction, then stirred at room 
temperature for 45 min. The mixture was cooled on an ice/salt bath and diethyl
99
oxalate (27.3 g, 0.187 mol) added dropwise over a period of 10 min. The mixture 
was then stirred at room temperature for 1.5 h, after which time ice, then aqueous 
3.7M NH4CI (250 ml) was added. The mixture was stirred for 10 min and extracted
with DCM (2 x 500 ml). A precipitate formed in the organic extract and this was 
filtered off and disguarded. The filtrate was dried (MgS04) and the solvent removed
in vacuo to leave a yellow oil which was triturated with ether and allowed to stand 
overnight. The precipitated solid was filtered off and recrystallised from DCM/n- 
hexane to give the title compound as a white solid (48.8 g, 57%). 
m.p. 189-191°C (lit130 188-189°C); Found: C, 84.4; H 5.36. C32H24O3 requires C, 
84.2; H, 5.26%; TLC: Rf (B) 0.5; 5H(360 MHz, CDC13): 8.79 (2H, d, J=8.3 Hz,
aromatic), 8.72 (2H, d, J=8.5 Hz, aromatic), 8.53 (2H, d, J=8.0 Hz, aromatic), 7.70- 
7.47 (12H, m, aromatic), 4.51 (1H, s, OH), 4.42 (2H, q, J=7.2Hz, CH2), 1.18 (3H, t, 
J=7.2 Hz, CH3); vmax(DCM): 3500 (OH), 3060 (aromatic CH), 1730 (ester C=0), 
1600 cm-1; ^ ^ (D C M ): 300 (e 20200 dnA noH cnr1), 289 (18900), 278 (25900), 
257 nm (103000); m/z (El): 456 (M+), 364, 363; HRMS: 456.1739, C32H2403 
requires 456.17253.
17-(Ethoxycarbonyl)-8Z>H-tetrabenzo[a,c,g,/]fluorene (68)
Ethyl (¿>A-phenanthren-9-yl)glycolate (27 g, 59.2 mmol) was taken in DCM (270 
ml) and TFA (81 ml) slowly added with stirring. After 20 min, the solvent was 
removed in vacuo and the residue triturated with ether to give the product as a 
yellow solid (23.1 g, 89%).
m.p. 161-163°C; Found: C, 86.5; H, 5.12. C32 H220 2 requires C, 87.7; H, 5.02%; 
TLC: Rf (B) 0.69; 5H(360 MHz, CDC13): 8.81-8.74 (2H, m. aromatic), 8.12-7.93
(3H, m, aromatic), 7.82-7.61 (6H, m aromatic), 7.47-7.29 (4H, m, aromatic), 7.11-
7.06 (1H, m, aromatic), 5.38 (1H, s, CH), 4.62-4.49 (2H, m, CH2), 1.41 (3H, t, J=7.2 
Hz, CH3); §c(50 M H z, CDCI3): 168.5 (ester C=0), 146.9 (quaternary aromatic C),
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138.3-123.2 (aromatic C's), 61.7 (CH2), 52.5 (CH), 13.9 (CH3); vmax(DCM):2960- 
2900 (CH), 1730 (ester C=0), 1610 cm"1 (aromatic C=C); ^ ^ (D C M ): 372 (e
10300 dm3mol-1cm-l), 301 (32200), 290 (31200), 254 nm (66500); m/z (El): 438 
(M+), 364, 363; HRMS: 438.1610, C32H2202 requires 438.16197.
17-(8£H-Tetrabenzo[a,c,g,i]fluorenyl)methanol (69)
17-(Ethoxycarbonyl)-8dH-tetrabenzo[a,c,g,/]fluorene (6.0 g, 13.7 mmol) was taken 
in DCM (300 ml) in an atmosphere of dry nitrogen and cooled to -65°C. A 1M 
solution of diisobutylaluminium hydride (41.4 ml, 41.4 mmol) in DCM was added 
dropwise, such that the temperature remained below -60°C. The mixture was then 
stirred at -70°C for 1 h and for a further 1.5 h at room temperature. The mixture was 
cooled to -30°C and 10% aqueous acetic acid (180 ml) carefully added. A solid 
precipitated and was filtered off, washed with water and taken up in DCM. The 
solution was dried (MgS04) and solvent removed in vacuo to give a yellow solid
which was recrystallised from DCM/n-hexane to give the title compound (3.78 g, 
70%).
m.p. 185-187°C; Found: C, 89.9; H, 5.13. C30 H20O requires C, 90.9; H, 5.05%; 
TLC: Rf (F) 0.75, (A) 0.07, (H) 0.08; vmax(DCM): 3600 (OH), 3080 (aromatic CH), 
2920 (aliphatic CH), 1610 cm-1 (aromatic C=C); ^ ^ (D C M ): 372 (e 9450 dm3mol'
W 1), 356 (7910), 299 (28600), 287 (29000), 253 nm (59800); m/z (FAB): 396 
(M+), 379, 366, 364; HRMS: 396.15142. C30H20O requires 396.15141.
17-(EthoxycarbonyI)tetrabenzo[a,c,g,i]fluorene (55)
17-(Ethoxycarbonyl)-86H-tetrabenzo[a,c,g,i']fluorene (15 g, 43.2 mmol) was taken 
in DCM (100 ml) and triethylamine (0.2 ml, 1.44 mmol) added with swirling. The 
solvent was then removed in vacuo and the residue triturated with ether to give the 
title compound as a yellow solid (14.5 g, 97%).
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m.p. 168-169°C (lit130 165-166°C); Found: C, 87.1; H, 5.02. C32 H220 2 requires C, 
87.7; H, 5.02%; TLC: Rf (B) 0.67; 6H(360 MHz, CDC13): 8.76-8.63 (6H, m.
aromatic), 8.27-8.24 (2H, m, aromatic), 7.70-7.57 (8H, m aromatic), 5.50 (1H, s, 
CH), 4.04 (2H, q, CH2), 0.96 (3H, t, CH3); 8C(50 MHz, CHC13): 172.6 (ester C=0),
138.8, 138.7, 132.2, 131.0, 129.2, 128.3 (quaternary aromatic C's), 128.2, 127.8,
126.8, 126.7, 125.6, 124.5, 123.8 (aromatic CH's), 62.1 (CH2), 55.4 (CH), 14.5 
(CH3); vmax(DCM): 3080 (aromatic CH), 2930 (aliphatic CH), 1725 (ester C=0), 
1610 cm_1 (aromatic C=C); ^ ^ (D C M ): 386 (e 15200 dm3mol"1cm"1), 370
(17500), 302 (47500), 290 (37800), 279 (32300), 262 (71400), 253 nm (76500); m/z 
(El): 438 (M+), 364, 363; HRMS: 438.1633, C32H220 2 requires 438.16197
17-Tetrabenzo[a,c,g,i]fluorenylmethanol (56)
(a) 17-(Ethoxycarbonyl)tetrabenzo[a,c,g,/]fluorene (6.0 g, 13.7 mmol) was taken in 
DCM (300 ml) in an atmosphere of dry nitrogen and cooled to -65 °C. A solution of 
1M diisobutylaluminium hydride (41.4 ml, 41.4 mmol) in DCM was added 
dropwise, such that the temperature remained below -60°C. The mixture was then 
stirred at -70°C for 1 h and for a further 2 h at room temperature. The mixture was 
cooled to -30°C and 20% aqueous acetic acid (90 ml) carefully added. The mixture 
was diluted with water (100 ml) and extracted with DCM (300 ml + 2 x 200 ml), the 
organic extract dried (MgSC^) and solvent removed in vacuo to give a yellow solid
which was washed with ether to give the title compound (4.8 g, 88%).
(b) 17-(86H-Tetrabenzo[a,c,g,/]fluorenyl)methanol (10.0 g, 25.3 mmol) was taken in 
DCM (200 ml) and triethylamine (0.2 ml) added. The mixture was swirled until all 
the solid had dissolved then the solvent was removed in vacuo and the residue 
triturated with ether to give the title compound (8.99 g, 90%).
m.p. 202-204°C (lit130 202-203°C); Found: C, 90.2; H, 5.17. C30 H20O requires C, 
90.9; H, 5.05%; TLC: Rf (C) 0.74; 5H(200 MHz, CDC13): 8.82-8.64 (6H, m.
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aromatic), 8.33-8.25 (2H, m, aromatic), 7.75-7.57 (8H, m aromatic), 5.15 (1H, t, 
J=4.3 Hz, CH), 4.43 (2H, d, J=4.3 Hz, CH2); vmax(DCM): 3580 (OH), 3010
(aromatic CH), 2910, 2890 (aliphatic CH), 1605 (aromatic C=C), 1495, 1035 cm '1; 
^ ( D C M ) :  380 (e 16500 dn^m oH cnr1), 366 (17600), 301 (40300), 289 (33000),
261 (61500), 253 nm (66700); m/z (FAB): 396 (M+), 379, 366; HRMS: 396.15142, 
C30H20O requires 396.15141.
(17-tetrabenzo[a,c,g,i]fluorenyl)methyl-p-nitrophenyl carbonate (72)
(17-tetrabenzo[a,c,g,/]fluorenyl)methanol (6.5 g, 16.4 mmol) was taken in DCM
(260 ml) along with p-nitrophenyl chloroformate (3.64 g, 18.1 mmol) and N,N-
dimethylaniline (2.63 ml, 20.8 mmol). The mixture was stirred for 4 days then the
solvent removed in vacuo and the residue re-dissolved in DCM and hexane added to
precipitate the crude product. The yellow solid was recystallised from
dioxane/hexane and a further product was obtained from the mother liquor on wet
flash chromatography using toluene as eluent. Yield 5.92 g (64%).
m.p. 210-213°C (lit130 139-140°C); TLC: Rf (H) 0.33; 8H(360 MHz, dioxane-d8):
9.18-9.14 (4H, m, aromatic), 8.92 (2H, dd J=8.3, 0.82 Hz), 8.64-8.60 (2H, m, 
aromatic), 8.23 (2H, d J=9.1 Hz, nitrophenyl m-CH), 8.03-7.79 (8H, m aromatic),
7.07 (2H, d J=9.1 Hz, nitrophenyl o-CH), 5.74 (1H, t, J=4.6 Hz, CH), 5.30 (2H, d, 
J=4.6 Hz, CH2); vmax(DCM): 3060 (aromatic CH), 1770 (C=0), 1620 (aromatic 
C=C), 1530, 1490, 1350, 1210 cm'1; ^ ( D C M ) :  366 (e 13400 dnA noH cnr1),
301 (33700), 289 (30200), 261 (53100), 254 nm (56100); m/z (FAB): 561 (M+), 
379, 234; HRMS: 561.15768, C37H2305N requires 561.15761.
N ^n-Tetrabenzof^c^ilfluorenylm ethoxycarbonyO -glycine (50)
Glycine (0.05 g, 0.667 mmol) was dissolved in 5% aqueous Na2C 0 3 (2ml) and
diluted with water (5 ml) and dioxane (3 ml) then added to a solution of (17-
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tetrabenzo[a,c,g,z']fluorenyl)methyl-/?-nitrophenyl carbonate (0.10 g, 0.178 mmol) in 
dioxane (10 ml). The mixture was stirred for 1.5 h then poured into water (30 ml) 
and washed with ether (2 x 50 ml). The aqueous mixture was acidified to pHl with 
2M KHSO4 and extracted with DCM (2 x 30 ml). The organic extract was washed 
with water and dried (MgSC^). The solvent was removed in vacuo and the residue 
triturated with ether to give the title compound (0.04 g, 45%). 
m.p. 224-225°C (lit130 240-241°C); m/z (FAB): 497 (M+), 379.
Ethyl 2-methoxy-2-(iWs-phenanthren-9-yl)acetate (76)
Ethyl (Zus-phenanthren-9-yl)glycolate (20 g, 43.9 mmol) was taken in DMSO (40 
ml) and powdered KOH (12 g, 0.214 mol) added, the mixture was stirred for 5 min 
then methyl iodide (5.5 ml) added and the mixture stirred for 15 min. Ice/water (300 
ml) was added and the mixture extracted with DCM (3 x 100 ml), the extract washed 
with water, dried (MgSC^) and the solvent removed in vacuo. The residue was
triturated with ether to give a white solid which was recrystallised from DCM/n- 
hexane to give a white solid (11.9 g, 57%).
m.p. 234-237°C; Found: C, 83.7; H, 5.44. C33H2603 requires C, 84.3; H, 5.53%; 
TLC: Rf (B) 0.55, Rf (G) 0.13; 5H(80 MHz, CDC13): 8.81-8.53 (6H, M, aromatic), 
7.78-7.32 (12H, m, aromatic), 4.31 (2H, q, J=7.1 Hz, CH2), 3.46 (3H, s, OCH3), 
1.11 (3H, t, J=7.1 Hz, CH3); vmax(DCM): 3068 (aromatic CH), 2991, 2942
(aliphatic CH), 1733 (ester C=0), 1600 (aromatic C=C), 1447, 1239, 1097 cm'1; 
^max(DCM): 301 (19700 dn^m oH cnr1), 290 (17900), 256 nm (103000); m/z
(FAB): 470 (M+), 439, 397, 365, 205.
2-Methoxy-2-(Ms-phenanthren-9-yl)ethanoI (77)
Ethyl 2-methoxy-2-(to-phenanthren-9-yl)acetate (11.7 g, 24.9 mmol) was taken in 
DCM (100 ml) and cooled to 0°C under an atmosphere of dry nitrogen. A 1M
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solution of diisobutylaluminium hydride in DCM (84 ml, 84.0 mmol) was added 
dropwise and then the solution allowed to stir at room temperature for 30 min. The 
reaction was quenched by the careful addition of 10% aqueous acetic acid and the 
mixture extracted with DCM (3 x 100 ml). The extract was washed with water (2 x 
100 ml) then dried (MgSC^) and the solvent removed in vacuo. The residue was
triturated with ether to give a white solid (7.9 g, 74 %).
m.p. 222-224°C; Found: C, 86.4; H, 5.44. C31H2402 requires C, 86.9; H, 5.60%; 
TLC: Rf (B) 0.18; 6H(B0 MHz, CDC13): 8.75-7.09 (18H, m, aromatic), 4.83 (2H, 
apparent br d, J=6.4 Hz, CH2), 3.24 (3H, s, CH3), 1.66-1.61 (1H, br m, exchanges 
with D20 , OH); vmax(DCM): 3576 (OH), 3080 (aromatic CH), 2982, 2897 (aliphatic 
CH), 1598 (aromatic C=C), 1495, 1446, 1118, 1055 cm’1; ^ ^ (D C M ): 301 (24400 
dm^moHcnr1), 289 (21300), 255 nm (120000); m/z (FAB): 398 (M+-OMe), 274, 
257, 232.
2-Methoxy-2-(Zus-phenanthren-9-yl)ethyl pentafluorophenyl carbonate (78)
2-Methoxy-2-(6ri-phenanthren-9-yl)ethanol (5.0 g, 11.7 mmol) was taken with 
triphosgene (1.18 g, 3.97 mmol) and triethylamine (1.65 ml, 11.8 mmol) and the 
mixture stirred in an atmosphere of dry nitrogen. After 30 min pentafluorophenol 
(2.5 g, 13.6 mmol) was added along with triethylamine (1.65 ml, 11.8 mmol) and the 
solution stirred overnight, the solvent was removed in vacuo and the residue purified 
by wet flash chromatography using 50% DCM/hexane as eluent. Fractions of Rf 0.47
were combined and the solvent removed in vacuo to leave a foam, which gave a 
white solid (3.91 g, 52%) on trituration with ether.
m.p. 167-169°C (decomp); Found: C, 70.8; H, 4.00. C3gH23C>4F5 requires C, 71.5; 
H, 3.61%; TLC: Rf (E) 0.87, Rf (D) 0.47, Rf (B) 0.66; 5H(200 MHz, CDC13): 8.95 
(6H, br s, aromatic), 8.68-7.17 (12H, br m, aromatic), 5.75 (2H, br s, CH2), 3.40 
(3H, s, CH3); 8C(50 M H z , CDC13): 150.9 (C=0), 143.5, 140.0, 138.5, 134.5, 131.1,
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130.5, 129.7 (quaternary aromatic C's), 129.1, 128.0, 127.3, 126.6, 126.2, 122.9,
122.2 (aromatic CH's), 69.9 (br, CH2), 51.2 (br, CH3); vmax(DCM): 2957 (CH), 
1789 (C=0 ), 1525, 1239, 986 cm '1; ^ ( D C M ) :  301 (24200 dnA noH cnr1), 289 
(21700), 255 nm (116000); m/z (FAB): 639 (M+), 608.
N-(2-Methoxy-2-(£is-phenanthren-9-yl)ethoxycarbonyI)butyIamine (79)
2-Methoxy-2-(6/.v-phenanthren-9-yl)ethyl pentafluorophenyl carbonate (0.50 g, 
0.785 mmol) was taken in DCM (5 ml) and n-butylamine (0.233 mmol) added. The 
mixture was stirred for 5 min then the organic layer extracted with with water (3 x 
10 ml), washed with 2m KHSO4 and dried (MgSC^). The solvent was removed in
vacuo and the residue triturated with ether to give a white solid (0.31 g, 75%). 
m.p. 112-118°C ; Found: C, 80.8; H, 6.52; N, 2.50. C36H33N0 3 requires C, 82.0; H, 
6.26; N, 2.66%; TLC: Rf (E) 0.29; 5H(200 MHz, CDC13): 8.66 (6H, d J=8.7 Hz, 
aromatic), 7.96-7.22 (12H, m, aromatic), 5.36 (2H, br s, CH2), 4.39 (1H, br t, NH), 
3.25 (3H, s, OCH3), 3.04-2.95 (2H, m, a-CH), 1.29-0.92 (7H, m, 2xCH2, CH3); 
vmax(DCM): 3449 (NH), 1724 (urethane C=0), 1520, 1221, 1128 cm '1;
^axCDCM): 302 (24400 d rF m o F cn r1), 257 nm (114000); m/z (FAB): 496 (M- 
OMe), 411, 397, 379.
N°c_(i7_Tetrabenzo[a,c,g,i]fluorenylmethoxycarbonyl)-L-methionine t-butyl 
ester, Tbfmoc-L-Met-OtBu
L-Methionine t-butyl ester143 (2.0 g, 9.85 mmol) was dissolved in glacial acetic acid 
(4.0 ml). The solution was lyophilised and the residue washed with a little ether to 
give the acetate salt as a white solid (2.08 g, 80%).
(17-Tetrabenzo[<3,c,g,/]fluorenyl)methyl-p-nitrophenyl carbonate (0.5 g, 0.891 
mmol) and L-methionine t-butyl ester acetate (0.28 g, 1.06 mmol) were dissolved in 
dichloromethane (20 ml). N,N-Dimethylaniline (0.22 g, 1.74 mmol) was added and
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the mixture stirred at room temperature in an atmosphere of dry nitrogen for 4 days. 
Water (30 ml) was then added and the mixture acidified to pHl with 2M KHSO4.
The mixture was extracted with dichloromethane (3 x 20 ml), the combined extracts 
washed with water (30 ml), dried (MgS04) and the solvent removed in vacuo to
leave an orange oil. The oil was taken up in ether and the product precipitated by the 
slow addition of n-hexane. Recrystallisation from ether/n-hexane gave the title 
compound as an off-white solid (0.219 g, 39%).
m.p. 148.5-150°C; Found: C, 75.9; H, 5.90; N, 2.27. C4oH37N0 4S requires C, 76.6; 
H, 5.90; N, 2.23%; TLC: Rf (B) 0.12; [a ]D25 -13.8° (c=l, DCM); 5H(200 MHz, 
CDCI3): 8.83-8.64 (6H, m, aromatic), 8.33 (2H, d, J=7.8 Hz, aromatic), 7.75-7.57 
(8H, m aromatic), 5.31-5.18 (2H, m, CH and NH), 4.60 (2H, m, CH2), 4.32 (1H, m, 
CH), 2.40 (2H, m, CH2), 2.03 (3H, s, SMe), 1.85 (2H, m, p CH2), 1.45 (9H, s, t- 
Bu); 5C(50 MHz, CDC13): 170.7, (CO, ester), 155.5 (CO, urethane), 142.1, 141.4,
136.6, 131.3, 128.5, 127.7 (aromatic quaternary C's), 127.2, 126.7, 125.9, 125.7,
125.3, 125.0, 124.8, 123.3, 123.0 (aromatic CH's), 82.1 (C-Me3), 68.7 (CH2), 53.4 
(CH), 47.3 (CH), 32.0 (CH2), 29.5 (CH2), 27.8 (CH3 x 3), 15.2 (S-CH3); 
vmax(DCM): 3410 (urethane NH), 3040 (aromatic CH), 2960, 2920 (aliphatic CH), 
1720 (C=0), 1610 (aromatic C=C), 1500, 1215, 1155, 1050 cm'1; ^ ^ (D C M ): 380
(18800 dm^moHcnr1), 375 (20500), 300 (24200), 288 (38800), 260 (74100), 252 




Noc_(i7_Tetrabenzo[a,c,g,/]fluorenylmethoxycarbonyl)-L-methionine t-butyl ester, 
Tbfmoc-L-Met-C^Bu (0.2 g, 0.319 mmol) was dissolved in trifluoroacetic acid (10 
ml), together with ethyl methyl sulphide (0.2 ml), ethanedithiol (0.2 ml) and
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thioanisole (0.2 ml). The mixture was stirred under nitrogen for 2 h then the solvent 
removed in vacuo and the residue dissolved in ethyl acetate. n-Hexane was added 
slowly and, after chilling overnight, the title compound precipitated as an off-white 
solid (0.155 g, 85%), m.p. 167-171°C (decomp); TLC: Rf (F) 0.51; HPLC: column 
A, gradient 4 Rt 27.5 min; vmax(DCM): 3410 (urethane NH), 3080 (aromatic CH),
2920 (aliphatic CH), 1720 (C=0), 1610 (aromatic C=C), 1510, 1050 cm '1; 
^ ( D C M ) :  382 (14800 dn^m oH cnr1), 376 (16200), 302 (40500), 290 (34800), 
254 (66700); m/z (FAB): 571 (M+), 379; HRMS: 571.18173, C36H29N04S requires 
571.18172
Na-(17-Tetrabenzo[a,c,g,i]fluorenyImethoxycarbonyl)-L-leucine t-butyl ester, 
Tbfmoc-L-Leu-O^Bu
L-Leucine t-butyl ester (0.2 g, 0.894 mmol) hydrochloride was taken in ethyl acetate 
(5 ml) and triethylamine (0.125 ml; 0.894 mmol) added. The mixture was stirred 
under an atmosphere of dry nitrogen overnight and the precipitated triethylamine 
hydrochloride filtered off and washed with ethyl acetate (5 ml). The solvent was 
removed from the combined filtrate in vacuo and the residue dissolved in glacial 
acetic acid (2 ml) then lyophilised. The residue was triturated with ether to give 
leucine t-butyl ester acetate as a white solid (0.1 g).
(17-Tetrabenzo[a,c,g,/]fluorenyl)methyl-/?-nitrophenyl carbonate (0.2 g, 0.357 
mmol) and L-leucine t-butyl ester acetate (0.097 g, 0.393 mmol) were dissolved in 
dichloromethane (8 ml). N,N-Dimethylaniline (0.086 ml, 0.71 mmol) was added and 
the mixture stirred at room temperature in an atmosphere of dry nitrogen for 7 days. 
Water (10 ml) was then added and the mixture acidified to pHl with 2M KHS04.
The mixture was extracted with dichloromethane (3 x 10 ml), the combined extracts 
washed with water (10 ml), dried (MgS04) and the solvent removed in vacuo to
leave an orange oil. The product was purified by dry flash chromatography
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(DCM/MeOH). Fractions of Rf 0.10 (E) were combined and the solvent removed in 
vacuo. The residue was triturated with n-hexane to give the title compound as an off- 
white solid (0.075 g, 34%)
m.p. 151-154°C (decomp); Found: C, 79.7; H, 6.30; N, 2.30. C41H39N 04 requires 
C, 80.8; H, 6.40; N, 2.30%; TLC: Rf (F) 0.81, Rf (E) 0.10; [a ]D25 -36.4° (c=0.25, 
DCM); 8h (360 MHz, CDC13): 8.81-8.76 (4H, m, aromatic), 8.66 (2H, d, J=8.2 Hz,
aromatic), 8.35 (2H, t, J=8.6 Hz, aromatic), 7.70-7.59 (8H, m, aromatic), 5.28 (1H, t, 
J=5.9 Hz, ring CH), 4.95 (1H, d, J=8.8 Hz, NH), 4.59 (2H, br s, CH2), 4.27-4.23 
(1H, m, ct-CH), 1.62-1.50 (3H, m, y-CH & (3-CH2), 1.45 (9H, s, 3 x CH3), 0.92- 
0.89 (6H, m, 2 x CH3); vmax(DCM): 3415 (urethane NH), 3030 (aromatic CH),
2980-2875 (aliphatic CH), 1720 (C=0), 1610 (aromatic C=C), 1510 cm '1; 
^axiDCM ): 382 (17600 dn^moHcm-1), 367 (18900), 302 (45300), 290 (35500), 




L-Isoleucine t-butyl ester (0.5 g, 2.24 mmol) hydrochloride was taken in ethyl 
acetate (15 ml) and triethylamine (0.313 ml; 2.24 mmol) added. The mixture was 
stirred under an atmosphere of dry nitrogen for 1 h and the precipitated triethylamine 
hydrochloride filtered off and washed with ethyl acetate (5 ml). The solvent was 
removed from the combined filtrate in vacuo and the residue dissolved in glacial 
acetic acid then lyophilised. The residue was triturated with n-hexane to give 
isoleucine t-butyl ester acetate as a white solid (0.405 g, 73%). 
(17-Tetrabenzo[a,c,g,/]fluorenyl)methyl-p-nitrophenyl carbonate (0.5 g, 0.891 
mmol) and L-isoleucine t-butyl ester acetate (0.24 g, 0.984 mmol) were dissolved in 
dichloromethane (20 ml). N,N-Dimethylaniline (0.217 ml, 1.78 mmol) was added
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and the mixture stirred at room temperature in an atmosphere of dry nitrogen for 4 
days. Water (20 ml) was then added and the mixture acidified to pHl with 2M 
KHSO4 and the mixture extracted with dichloromethane (3 x 20 ml). The combined 
extracts were washed with water (20 ml), dried (MgSC^) and the solvent removed in 
vacuo to leave an orange oil. The residue was taken up in ether and the product 
precipitated by the addition of n-hexane to give the title compound as a pale orange 
solid (0.25 g, 46%).
m.p. 159-161°C (decomp); Found: C, 79.7; H, 6.16; N, 2.30. C ^ I^ N C ^  requires 
C, 80.8; H, 6.40; N, 2.30%; TLC: Rf (F) 0.81, Rf (E) 0.10; [cc]D25 +3.0° (c=0.5, 
DCM); 5h (360 MHz, CDC13): 8.79 (4H, t J=8.7 Hz, aromatic), 8.67 (2H, d, J=8.2
Hz, aromatic), 8.39-8.33 (2H, m, aromatic), 7.78-7.59 (8H, m, aromatic), 5.32 (1H, 
t, J=6.2 Hz, ring CH), 5.15 (1H, d, J=9.1 Hz, NH), 4.58 (2H, t J=5.7 Hz, CH2), 4.24- 
4.20 (1H, m, cc-CH), 1.46 (9H, s, 3 x CH3), 1.43-1.38 (2H, m, CH2), 0.93-0.85 (6H, 
m, 2 x CH3); 8^(50 MHz, CDCI3): 170.7, (CO, ester), 155.8 (CO, urethane), 142.1,
141.8, 136.6, 131.4, 130.2, 128.6, 127.8 (aromatic quaternary C's), 127.3, 126.8,
126.6, 125.7, 125.5, 124.8, 123.4, 123.0 (aromatic CH's), 81.7 (C-Me3), 68.9 (CH2),
58.4 (CH), 47.5 (CH), 27.9 (CH3 x 3), 24.8 (CH2), 15.2 (CH3), 11.6 (CH3); 
vmax(DCM): 3415 (urethane NH), 3030 (aromatic CH), 2980-2875 (aliphatic CH), 
1720 (C=0), 1610 cm-1 (aromatic C=C); T^^CDCM): 382 (16700 dn^m oH cnr1),
367 (18300), 302 (44200), 290 (35100), 262 (67000), 254 (70000); m/z (FAB): 609 
(M+), 379; HRMS: 609.28784, C ^ qNC^ requires 609.28789.
Na-(17-Tetrabenzo[a,c,g,i]fluorenylmethoxycarbonyl)-L-alanine t-butyl ester, 
Tbfmoc-L-AIa-O^Bu
L-Alanine t-butyl ester (0.44 g, 2.42 mmol) hydrochloride was taken in ethyl acetate 
(13 ml) and triethylamine (0.338 ml, 2.42 mmol) added. The mixture was stirred for 
3 h and the precipitated triethylamine hydrochloride filtered off and washed with
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ethyl acetate (5 ml). The solvent was removed from the combined filtrate in vacuo to 
leave L-alanine t-butyl ester.
(17-Tetrabenzo[a,c,g,/]fluorenyl)methyl-/?-nitrophenyl carbonate (0.5 g, 0.891 
mmol) and L-alanine t-butyl ester (0.142 g, 0.98 mmol) were dissolved in 
dichloromethane (20 ml) along with acetic acid (0.056 ml, 0.98 mmol). N,N- 
Dimethylaniline (0.217 ml, 1.78 mmol) was added and the mixture stirred at room 
temperature in an atmosphere of dry nitrogen for 7 days. The solvent was then 
removed in vacuo to leave an orange oil and the product purified by dry flash 
chromatography using DCM as eluent. Fractions of Rf 0.12 (E) were combined and
the solvent removed in vacuo. The residue was triturated with ether to give the title 
compound as a white solid (0.210 g, 42%)
m.p. 148-150°C (decomp); Found: C, 80.1; H, 5.82; N, 2.50. C38H33NO4 requires 
C, 80.4; H, 5.82; N, 2.47%; TLC: Rf (E) 0.12; [a ]D25 +2.0° (c=0.5, DCM); 5H(360 
MHz, CDCI3): 8.78 (4H, t J=8.5 Hz, aromatic), 8.66 (2H, d J=8.2 Hz, aromatic),
8.35-8.31 (2H, m, aromatic), 7.77-7.59 (8H, m, aromatic), 5.28 (1H, m, ring CH), 
5.15 (1H, d J=7.7 Hz, NH), 4.62-4.54 (2H, m, CH2), 4.25-4.21 (1H, m, a-CH), 1.46 
(9H,s, t-Bu), 1.31 (3H, d J=7.1 Hz, CH3); Sc (50 MHz, CDC13): 171.8 (CO, ester),
155.3 (CO, urethane), 142.1, 141.6, 136.6, 131.3, 130.1, 128.6, 127.8 (aromatic 
quaternary C's), 127.2, 126.7, 125.9, 125.4, 125.1, 124.8, 123.3, 123.0 (aromatic 
CH's), 81.7 (C-Me3), 68.7 (CH2), 49.8 (CH), 47.3 (CH), 27.7 (CH3 x 3), 18.7 
(CH3); vmax(DCM): 3415 (urethane NH), 3030 (aromatic CH), 2980-2885 (aliphatic 
CH), 1720 (C=0), 1610 (aromatic C=C), 1500 cm’1; ^ ^ (D C M ): 380 (17900
dm^moHcnr1), 365 (19200), 300 (45900), 288 (36200), 253 (74240); m/z (FAB): 
567 (M+), 379; HRMS: 567.24094, C38H33N04 requires 567.24095.
i l l
N0—(17-Tetrabenzo[a,c,g,i]fluorenylmethoxycarbonyl)-L-valine t-butyl ester, 
Tbfmoc-L-Val-OtBu
L-Valine t-butyl ester hydrochloride (0.5 g, 2.38 mmol) was taken in ethyl acetate 
(15 ml) and triethylamine (0.333 ml; 2.38 mmol) added. The mixture was stirred 
under an atmosphere of dry nitrogen for 3 h and the precipitated triethylamine 
hydrochloride filtered off and washed with ethyl acetate (5 ml). The solvent was 
removed from the combined filtrate in vacuo and the residue dissolved in glacial 
acetic acid (2 ml) then lyophilised. The residue was triturated with n-hexane to give 
valine t-butyl ester acetate as a white solid (0.424 g, 81%).
(17-Tetrabenzo[a,c,g,i]fluorenyl)methyl-/?-nitrophenyl carbonate (0.5 g, 0.891 
mmol) and L-valine t-butyl ester acetate (0.23 g, 0.98 mmol) were dissolved in 
dichloromethane (20 ml). N,N-Dimethylaniline (0.217 ml, 1.78 mmol) was added 
and the mixture stirred at room temperature in an atmosphere of dry nitrogen for 7 
days. Water (20 ml) was added, the mixture acidified to pHl with 2M KHSO4 and 
extracted with DCM (3 x 20 ml). The combined extracts were dried (MgSO,^) and
the solvent removed in vacuo to leave an orange oil. The product was purified by dry 
flash chromatography using DCM as eluent. Fractions of Rf 0.14 (E) were combined
and the solvent removed in vacuo. The residue was triturated with ether and the 
precipitated solid recrystallised from DCM/n-hexane to give the title compound as a 
white solid (0.297 g, 56%).
m.p. 159-163°C (decomp); Found: C, 81.0; H, 6.44; N, 2.37. C4oH37N04 requires 
C, 80.7; H, 6.22; N, 2.35%; TLC: Rf (E) 0.14; [a ]D25 -3.7° (c=l, DCM); 6H(360 
MHz, CDCI3): 8.79-8.74 (6H, m, aromatic), 8.66-8.63 (2H, m, aromatic), 7.79-7.58 
(8H, m, aromatic), 5.23-5.17 (2H, m, ring CH & NH), 4.61-4.49 (2H, m, Off?),
4.24-4.20 (1H, m, oc-CH), 2.17-2.11 (1H, m, CH), 1.49 (9H, s, t-Bu), 0.93 (3H, d 
J=6.9 Hz, CH3), 0.81 (3H, d J=6.9 Hz, CH3); 5C(50 MHz, CDC13): 170.8 (CO,
ester), 156.0 (CO, urethane), 142.0, 141.8, 136.5, 131.3, 130.1, 128.6, 127.8
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(aromatic quaternary C's), 127.3, 126.7, 126.6, 125.9, 125.7, 125.5, 125.2, 124.8,
123.3, 123.0 (aromatic CH’s), 81.7 (C-Me3), 69.0 (CH2), 59.0 (CH), 47.5 (CH), 31.2 
(CH), 27.9 (CH3 x 3), 18.7 (CH3), 17.1 (CH3); vmax(DCM): 3410 (urethane NH),
3060 (aromatic CH), 2960 (aliphatic CH), 1720 (C=0), 1610 (aromatic C=C), 1510 
«an-1; ^ ^ (D C M ): 380 (18800 dn^m oH cnr1), 365 (20200), 300 (48600), 288




N“- (  17-Tetrabenzo[a,c,g,z]fluorenylmethoxycarbonyl)-L-valine t-butyl ester, 
Tbfmoc-L-Val-O^u (0.5 g, 0.84 mmol) was taken in TFA (9.5 ml)/H20  (0.5 ml)
and stirred for 1 h. The solvent was then removed in vacuo and the residue triturated 
with ether to give the title compound as an off-white solid (0.408 g, 90%). 
m.p. 186-190°C (decomp); Found: C, 79.8; H, 5.65; N, 2.55. C3gH29N 04 requires 
C, 80.2; H, 5.38; N, 2.60%; TLC: Rf (F) 0.58; [a ]D25 +40.5° (c=l, dioxane); 
5fj(360 MHz, dioxane d-8): 9.06-8.99 (4H, m, aromatic), 8.83 (2H, d J=7.8 Hz,
aromatic), 8.66-8.62 (2H, m, aromatic), 7.97-7.75 (8H, m, aromatic), 6.56 (1H, d J=
9.2 Hz, NH), 5.66-5.60 (1H, t J=5.8 Hz, ring CH), 4.91-4.82 (2H, m, CH2), 4.74- 
4.65 (1H, m, a-CH), 2.24-2.14 (1H, m, (3-CH), 1.01-0.93 (6H, m, 2 x CH3); 
vmax(DCM): 3504 (OH), 3455 (NH), 3068 (aromatic CH), 2984 (aliphatic CH), 
1728 (C=0), 1609 (aromatic C=C), 1518 cm '1; ^ ^ (D C M ): 382 (17300 d r n W '
W 1), 367 (18700), 302 (45100), 289 (35900), 260 (64700), 252 (70100); m/z 
(FAB): 540 (MH+), 379; HRMS: 539.20968, C36H29N 04 requires 539.20965.
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Triphosgene (1.35 g, 4.55 mmol) was taken in ether (100 ml) with pentafluorophenol 
(4.0 g, 21.7 mmol) and cooled on an ice-salt bath. Triethylamine (4.08 ml, 29.3 
mmol) was added and the mixture allowed to warm to room temperature over 30 
min. The precipitated solid was filtered off and discarded. The solvent was removed 
in vacuo and the residue recrystallised from n-hexane to give the title compound as 
white crystals (3.04 g, 71%).
m.p. 48-50°C (lit153 48-50°C); vmax(DCM): 1810 (carbonate C=0), 1531, 1220, 
1011 cm-1
(17-Tetrabenzo[a,c,g,i]fluorenyI)methyl pentafluorophenyl carbonate (85) 
Dipentafluorophenyl carbonate (1.0 g, 2.54 mmol) was taken in DCM (20 ml) with 
17-tetrabenzo[a,c,g,i]fluorenylmethanol (1.06 g, 2.54 mmol) in an atmosphere of dry 
nitrogen and cooled to 0°C. Pyridine (0.204 ml, 2.54 mmol) was added and the 
solution stirred for 2.5 h. Water (20 ml) was added and the mixture acidified to pH 1 
with 2M KHSO4. The organic layer was separated and washed with water (2 x 10 
ml), dried (MgSO^), the solvent removed in vacuo and the residue purified by dry
flash chromatography using DCM/n-hexane as eluent. Fractions containing material 
of Rf 0.46 (D) were combined, the solvent removed in vacuo and the residue
triturated with ether to give the title compound as a pale yellow solid (0.97 g, 60%). 
m.p. 186-189°C; Found: C, 73.4; H, 3.37. C37H 190 3F5 requires C, 73.3 H, 3.14%; 
TLC: Rf (D) 0.46, Rf (E) 0.75; 8H(200 MHz, CDC13): 8.80-8.76 (4H, m. aromatic),
8.62 (2H, d J=7.8 Hz, aromatic), 8.23-8.18 (2H, m, aromatic), 7.77-7.58 (8H, m 
aromatic), 5.22 (1H, t J—5.5 Hz, CH), 4.86 (2H, d J=5.5 Hz, CH2); 8(2(50 MHz,
CDCI3): 150.8, (CO), 143.5, 143.2, 140.2, 140.1, 139.7, 138.4, 138.2, 136.9, 134.9,
131.4, 130.3, 128.0 (aromatic quaternary C's), 127.5-123.3 (aromatic CH's), 74.5 
(CH2), 45.2 (CH); SF(75 MHz, CDC13): '152.4- '153.2 (m), '156.8 - '157.3 (m),
Dipentafluorophenyl carbonate
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-161.2--162.0 (m); vmax(DCM): 3080 (aromatic CH), 2935, 2920 (aliphatic CH), 
1780 (carbonate C=0) 1610 (aromatic C=C), 1527 cm-1; A^ax^CM): 366 (e 19200
dmSmoHcnr1), 301 (45500), 289 (36900), 261 (67700), 253 nm (72200); m/z 
(FAB): 606 (M+), 379, 378, 363; HRMS: 606.12541, C37H 1903F5 requires
606.12542.
(17-Tetrabenzo[a,c,g,z]fluorenyl)methyI chloroformate (70) 
17-Tetrabenzo[a,c,g,z]fluorenylmethanol (1.0 g, 2.52 mmol) was taken in DCM (20 
ml) along with triphosgene (0.5 g, 1.68 mmol) and N,N-dimethylaniline (0.64 ml,
5.04 mmol) added. The mixture was stirred for 45 min and the precipitated solid 
filtered off and recrystallised from DCM/hexane to give the title compound as a pale 
yellow solid (0.577 g). A further crop of product was obtained from the DCM filtrate 
after adding water, acidifying to pHl with 2M HC1, drying the organic layer 
(MgS04), removing the solvent and recrystallising the residue from DCM/n-hexane.
Total yield (0.819 g, 71%).
m.p. 194-195°C (lit130 188-189°C); Found: C, 81.3; H, 4.22; Cl, 7.66. C31H 190 2C1 
requires C, 81.1; H, 4.14; Cl 7.74%; TLC: Rf (E) 0.75; 8H(200 MHz, CDC13): 8.80-
8.75 (6H, m. aromatic), 8.63 (2H, d J=8.0 Hz, aromatic), 8.20-7.57 (8H, m, 
aromatic), 5.20 (1H, t J=5.8 Hz, CH), 4.78 (2H, d J=5.8 Hz, CH2); 8C(90 MHz,
dioxane d-8): 149.5, (CO), 140.9, 136.7, 131.4, 130.3, 128.2, 127.6 (aromatic 
quaternary C's), 127.1, 126.6, 125.9, 125.8, 124.8, 124.5, 123.4 (aromatic CH's),
74.3 (CH2), 46.3 (CH); vmax(DCM): 3069 (aromatic CH), 2980 (aliphatic CH), 1776 
(carbonate C=0) 1611 (aromatic C=C), 1504, 1142 cm-1; ^ ^ (D C M ): 368 (e 17600
dn^m oH cnr1), 302 (43000), 290 (33800), 254 nm (66200); m/z (FAB): 460, 458 
(M+); HRMS: 458.10737, C31H190 2C1 requires 458.10735.
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Methyl 2-bromobenzoate160 (94)
N-Bromosuccinimide (130.0 g, 0.73 mol) and a catalytic amount of dibenzoyl 
peroxide were added to a solution of methyl 2-methylbenzoate (100.0 g, 0.66 mol) in 
carbon tetrachloride (1.0 1). The mixture was heated under reflux and irradiated with 
a 500 W Halogen lamp for 2 h, switching the lamp off periodically to control the 
vigour of the reaction. The cooled mixture was then filtered and the filtrate 
concentrated in vacuo to give the title compound as a yellow oil (191.9 g, 
overweight), which was used without further purification.
2-(Methoxycarbonyl)benzyltriphenyIphosphonmm bromide160 (95)
Methyl 2-bromobenzoate (191.9 g) was dissolved in toluene (1.0 1) together with 
triphenylphosphine (173.2 g, 0.66 mol) and the mixture stirred overnight. The 
resulting precipitate was filtered off, washed with toluene and recrystallised from 
DCM/toluene to give the title compound as a white solid (253.1 g, 78%), m.p. 234- 
238 °C (lit160 230-235°C).
2-(3'-Methoxyphenylethenyl)benzoic acid (101)
2-(Methoxycarbonyl)benzyltriphenylphosphonium bromide (200.0 g, 0.41 mol) and 
m-anisaldehyde (58.4 g, 0.43 mol) were stirred in dioxane (700 ml) under an 
atmosphere of dry nitrogen. A solution of DBU (64.4 g, 0.42 mol) in dioxane (100 
ml) was added and the mixture stirred at 50°C for 3 h. After cooling, the precipitated 
DBU hydrobromide was filtered off and washed with dioxane (400 ml). Water (320 
ml) then aqueous 2M NaOH (400 ml) were added to the filtrate and the mixture was 
heated under reflux for 45 min. The solution was then concentrated in vacuo, water 
(1.8 1) added and the precipitated solid filtered off and washed with water (200 ml). 
The combined filtrate was washed with ethyl acetate (2 x 500 ml) and ice added to 
the aqueous layer, which was then acidified to pHl with 2M aqueous HC1. A white
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solid precipitated which was filtered off, taken up in ether, dried (MgS04) and the 
solvent removed in vacuo to give the title compound as a white solid (39.7 g). 
Further product was obtained by extraction of the aqueous filtrate with ether (3 x 300 
ml). The ethereal extract was dried (MgS04), and the solvent removed in vacuo to
give an orange oil, which, on trituration with n-hexane gave the acid as a white solid 
(40.1 g), total yield (79.8 g, 77%). Found: C, 75.5; H, 5.63; C16H 140 3 requires C, 
75.6; H, 5.51; Rf (C) 0.17; 8H(200 MHz, (%-DMSO): 13.06 (1H, br s, COOH), 8.11- 
6.84 (10H, m, aromatic & alkene CH's), 3.77 & 3.52 (3H, s, cis & trans OCH3); 
5C(50 MHz, (%-DMSO): 169.1 & 168.4 (COOH, cis & trans), 159.9 & 159.2
(quaternary aromatic C-OMe, cis & trans), 139.0-112.5 (aromatic C's & alkene C's),
55.2 & 54.8 (CH3, cis & trans); vmax(DCM): 3504 (OH), 3060-2436 (OH), 1728
(C=0), 1688 (C=0), 1609 (C=C), 1518 cm '1; ^ (M e O H ): 302 (e 19100 dm3moT 
215 nm (19600); m/z(EI): 254, 194, 165.
2-(3'-Methoxyphenylethyl)benzoic acid (98)
2-(3'-Methoxyphenylethenyl)benzoic acid (100.0 g, 0.39 mol) was dissolved in 
methanol (1.0 1). 10% Pd/C (5.0 g) was added whilst the solution was cooled on an 
ice bath and stirred under an atmosphere of dry nitrogen. The mixture was then 
gently warmed to redissolve precipitated acid and, after allowing to cool to room 
temperature, was hydrogenated for 8 h. Ethyl acetate was then added to dissolve the 
precipitated product and the catalyst was filtered off on celite. The celite was washed 
with ethyl acetate to recover any undissolved product then the solvent was removed 
in vacuo and the residue recrystallised from methanol to give the title compound as a 
white solid (96.0 g, 95%).
m.p. 119-121°C (lit160 120-120.5°C); Found: C, 75.0; H, 6.33. C16H160 3 requires C, 
75.0; H, 6.30%; Rf (C) 0.26; 5jq (80 MHz, CDC13): 11.70 (1H, s, exchanges with 
D20 , -COOH); 8.18-6.70 (8H, m, aromatic); 3.79 (3H, s, -OCH3); 3.50-2.86 (4H, m,
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-CH2- x 2); 8^(50 M H z , dg-DMSO): 169.2 (COOH), 159.6 (quaternary aromatic, C- 
OMe), 143.7, 143.1 (quaternary aromatic C's) 131.9, 131.2 (aromatic CH's), 130.8 
(quaternary aromatic), 130.6, 129.5, 126.4, 120.9, 114.2, 111.5 (quaternary aromatic 
CH's), 55.0 (CH3), 37.9 (CH2), 36.4 (CH2); vmax(CH2Cl2): 3500 & 3400-2400 (OH),
1749 & 1695 (C=0), 1600 cm-1 (C=C); Xmax(MeOH): 280 (e 5180 dnA noF cnr1), 
273 (4970), 209 nm (35200); m/z(EI): 256, 238, 121.
2-Methoxydibenzocycloheptadien-5-one (99)
2-(3'-Methoxyphenylethyl)benzoic acid (1.5 g, 5.9 mmol) was taken in dry benzene 
(3 ml) and oxalyl chloride (1.5 ml) added while the mixture was cooled on an ice/salt 
bath. The mixture was stirred at room temperature under an atmosphere of dry 
nitrogen for 2 h, after which time the acid had dissolved and gas evolution had 
ceased. Excess oxalyl chloride and benzene were removed in vacuo and the residue 
taken up in dry benzene (1.5 ml). The benzene solution was then added to a stirred, 
cooled solution of tin (IV) chloride (3.2 g) in benzene (1.5 ml) over a period of 15 
min. Ice, then concentrated HC1 (3 ml) were added and the mixture heated until the 
precipitated solid had dissolved. After cooling, the organic layer was separated, 
taken up in ether, washed with water then brine and dried (MgS04). The solvent was
removed in vacuo to leave a brown oil which was triturated with n-hexane to give a 
pale brown solid. Recrystallisation from ether/n-hexane gave the title compound 
(1.05 g, 76%).
m.p. 75-76°C (lit160 75.5-76.0°C); Found: C, 80.3; H, 5.93. C 16H 140 2 requires C, 
80.6; H, 5.9%; Rf (E) 0.46, Rf (A) 0.28); 5H(360 MHz, CDC13): 8.16 (1H, d, J=8.9
Hz, aromatic); 8.01 (1H, dd, J=7.7, 1,5 Hz, aromatic); 7.41-7.25 (2H, m, aromatic);
7.18 (1H, dd, J=7.5, 1.1 Hz, aromatic); 6.84 (1H, dd, J=8.9, 2.6 Hz, aroamtic); 6.68 
(1H, d, J=2 Hz); 3.83 (3H, s, OMe); 3.14 (4H, s, -CH2 x 2); 5C(50 MHz, CDC13):
192.8 (CO), 162.5 (quaternary aromatic, C-OMe), 144.9, 141.3, 138.7 (quaternary
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aromatic C's), 133.5, 131.8, 130.3, 128.4, 126.3, 113.9, 111.9 (aromatic CH's), 55.0 
(CH3), 35.5 (CH2), 34.4 (CH2); vmax(CH2Cl2): 1640 (C=0), 1600 cnr* (C=C); 
^^ (M eO H ): 302 (e 13300 dmSmoHcnr1), 238 (8300), 209 nm (14900): m/z (El): 
238, 210, 195, 165.
2-Hydroxydibenzocycloheptadien-5-one (100)
2-(3'-Methoxyphenylethyl)benzoic acid (30 g, 0.12 mol) was taken in dry benzene 
(60 ml) together with oxalyl chloride (30 g, 0.24 mol) and the mixture stirred in an 
atmosphere of dry nitrogen for 3.5 h, after which time the acid had dissolved and gas 
evolution had ceased. The benzene and excess oxalyl chloride were the removed in 
vacuo, the residue taken up in dry benzene (125 ml) and a suspension of anhydrous 
aluminium chloride (45 g, 0.34 mol) in dry benzene (125 ml) slowly added whilst 
cooling and stirring on an ice bath. The mixture was heated under reflux for 30 min 
then cooled on an ice/salt bath and 2M HC1 (300 ml) slowly added with mixing. The 
precipitated solid was filtered off, taken up in ether and the ethereal solution filtered 
to remove the dark insoluble solid. The filtrate was washed with water (100 ml) then 
dried (MgSC^) and the solvent removed in vacuo. The residue was recrystallised
from ether/n-hexane to yield pale needles (23.2 g). A further 0.7 g of product was 
obtained from the benzene layer of the acidified reaction mixture filtrate by 
extracting with 2M NaOH (2 x 100 ml), acidifying the extract to pHl with 2M HC1 
and extracting with ether. The additional product was obtained from the ethereal 
solution similarly to the main fraction of product. Total yield 23.9 g (91 %). 
m.p. 141-142°C (lit160 141-141.5°C); Found: C, 80.4; H, 5.38. requires
C, 80.4; H, 5.4%; Rf (A) 0.06, Rf (C) 0.31; SH(80 MHz, CDC13): 8.14-6.82 (7H, m, 
aromatic); 6.65 (1H, s, exchanges with D20 , OH); 3.12 (4H, s, -CH2 x 2); 8^(50 
MHz, CDC13): 192.2 (CO), 162.0 (quaternary aromatic, C-OH), 145.8, 141.9, 139.2 
(quaternary aromatic C's), 134.0, 132.2, 130.5, 129.0, 126.7, 116.1, 114.4 (aromatic
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CH's), 35.6 (CH2), 34.4 (CH2); vmax(CH2Cl2): 3570 (OH), 1640 (C=0), 1605 cm' 1 
(C=C); ^^(M eO H ): 302 (e 16700 dn^m oH cnr1), 240 (12300), 208 nm (28800); 
m/z (El): 224, 196, 181, 165.
2-CopoIy(styrene-l%-divinylbenzene)methoxydibenzocycIoheptadiene-5-one160
(102)
2-Hydroxydibenzocycloheptadien-5-one (5.0 g, 22.3 mmol) was dissolved in t- 
butanol/water (1:1, 50 ml) along with caesium hydroxide (3.75 g, 25 mmol). The 
solution was stirred for 10 min then the t-butanol removed in vacuo. The caesium 
salt was dried by azeotropic distillation with pyridine (2 x 100 ml) and DMF (3 x 
100 ml), then the salt was dissolved in DMF (50 ml) and added to 
chloromethylpolystyrene resin (10 g, 0.7 mmol Cl/g), preswollen in DMF (50 ml). 
The mixture was stirred for 4 days at 60°C, after which time the resin was filtered 
off and washed with copious DMF, isopropanol and finally DCM. The resin was 
dried in vacuo to yield 10.8 g of resin (94%).
vmax(KBr disc): 3100-3000 (Ar CH), 2920-2840 (CH), 1640 (C=0), 1600 cm' 1 
(C=C); Found: Cl <0.7%; expected for 100% loading 0%.
2-Copoly(styrene-1 % -divinylbenzene)methoxydibenzocycloheptadien-5-ol160 
(110)
THF (100 ml) was added to the above resin (0.7 mmol/g: 5.0 g, 3.5 mmol) along 
with lithium borohydride (0.6 g, 27.3 mmol) and the mixture heated under reflux for 
1 h under an atmosphere of dry nitrogen. The mixture was then cooled on an ice/salt 
bath and methanol (10 ml), followed by acetone (10 ml) slowly added with stirring. 
The resin was filtered off and washed with copious methanol, 0.001M HC1 then 
methanol. The resin was dried in vacuo to give 4.91 g of product.
120




2-Copoly(styrene-1 %-divinylbenzene)methoxydibenzocycloheptadiene-5-ol (0.7 
mmol/g: 2.5 g, 1.75 mmol) was taken in DMF (70 ml) along with 9- 
fluorenylmethylcarbamate (1.7 g, 7.1 mmol). Benzenesulphonic acid (0.1 g, 0.6 
mmol) was added and the mixture stirred overnight under an atmosphere of nitrogen. 
The resin was then filtered off, washed with copious DMF then DCM and dried in 
vacuo to leave the title compound as an off-white solid (2.67 g, functionality 0.57 
mmol/g by uv monitoring147).
vmax(KBr disc): 3420 (NH), 3100-2840 (CH), 1720-1660 (C=O),1600 cm' 1 (C=C);
N-t-ButyIoxycarbonyI-N'-2-copoly(styrene-l%-divinyIbenzene)methoxy- 
dibenzocycloheptadien-5-ylhydrazine160 (93)
2-Copoly(styrene-1 %-divinylbenzene)methoxydibenzocycloheptadiene-5-ol (0.7 
mmol/g: 1.5 g, 1.05 mmol) was taken in DCM (100 ml), along with t- 
butyloxycarbonylhydrazine (0.97 g, 7.3 mmol) and benzenesulphonic acid (0.08 g, 
0.51 mmol) added. The mixture was heated under reflux overnight and the resin 
filtered off, washed with copious DMF, DCM and ether to leave the title compound 
as a white solid (1.55 g).
Found: N, 1.55; expected for 100% loading 1.62%; vmax(KBr disc): 3410 & 3300 
(NH), 3100-2820 (CH), 1710 (C=O),1600 cm*1 (C=C).
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2-(Benzyloxycarboxymethoxy)dibenzocycloheptadien-5-one160 (103)
2-Hydroxydibenzocycloheptadiene-5-one (3.0 g, 13.4 mmol) was taken in acetone 
(100 ml) along with anhydrous potassium carbonate (18.5 g, 134 mmol) and benzyl- 
2-bromoacetate (3.09 g, 13.5 mmol) and the mixture stirred at room temperature 
overnight. The excess potassium carbonate was then filtered off and the filtrate 
concentrated in vacuo. The residue was taken up in ethyl acetate (50 ml) and washed 
with saturated sodium carbonate solution (3 x 25 ml), then water (25 ml). The 
organic layer was dried (MgSC^) and the solvent removed in vacuo to yield a white
solid which was washed with a little ether. Yield 4.45 g (89%). 
m.p. 80-82°C (lit160 81.5-82°C).
2-(Oxyacetic acid)dibenzocycloheptadien-5-one160 (104)
2-(Benzyloxycarboxymethoxy)dibenzocycloheptadien-5-one (4.0 g, 10.8 mmol) was 
dissolved in methanol (50 ml) along with 2M sodium hydroxide (11 ml) and the 
mixture heated under reflux for 1 h. The methanol was then removed in vacuo and 
water (50 ml) added to the residue. Ice was added and the mixture was acidified to 
pHl with 2M HC1. The aqueous layer was extracted with ethyl acetate (2 x 100 ml) 
and the organic layer dried (MgS04) and the solvent removed in vacuo to leave the
title compound as a white solid (2.8 g, 93 %). 
m.p. 164-166°C (lit160 164-165°C).
2-Copoly(styrene-l%-divinylbenzene)methylaminocarboxymethoxy- 
dibenzocycloheptadien-5-one (106)
2-(Oxyacetic acid)dibenzocycloheptadiene-5-one (2.97 g, 10.5 mmol) was taken in 
DMF (15 ml) together with diphenylphosphinic anhydride (4.39 g, 10.5 mmol) and 
N-methylmorpholine (1.11 g, 11.0 mmol) and the mixture stirred at room
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temperature for 15 min. The mixture was then added to aminopolystyrene resin (4.5 
g; 0.89 mmol NH2/g, 4.0 mmol), preswollen in DMF, together with N-
methylmorpholine (1.11 g, 11.0 mmol) and 2,6-lutidine (2.22 g, 20.7 mmol) and the 
mixture stirred at room temperature for 3 h, after which time the resin showed only 
pale blue to Kaiser test. The resin was filtered off, washed with copious DMF the 
DCM and dried in vacuo to yield a white solid (5.4 g). Quantitative Kaiser test 
showed only 0.003 mmol/g of unreacted NH2.
vmax(KBr disc): 3410-3300 (NH), 3080-2840 (CH), 1680-1630 (O O  x 2),1600 
(C=C), 1530 cm-1 (amide II).
2-CopoIy(styrene-l%-divinylbenzene)methyIaminocarboxymethoxy- 
dibenzocycloheptadien-5-oI (107)
THF (75 ml) was added to the above resin (3.0 g) along with lithium borohydride 
(0.4 g, 18.3 mmol) and the mixture heated under reflux for 1 h under an atmosphere 
of dry nitrogen. The mixture was then cooled on an ice/salt bath and methanol (10 
ml), followed by acetone (10 ml) slowly added with stirring. The resin was fdtered 
off and washed with copious methanol, 0.001M HC1 then methanol. The resin was 
dried in vacuo to give 2.81 g of product.
vmax(KBr disc): 3530 (OH), 3420 (NH), 3080-2840 (CH), 1660 (C=0 amide I), 




heptadiene-5-ol (2.0 g) was taken in DMF (70 ml) along with 9- 
fluorenylmethylcarbamate (1.7 g, 7.1 mmol). Benzenesulphonic acid (0.1 g, 0.6 
mmol) was added and the mixture stirred overnight under an atmosphere of nitrogen.
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The resin was then filtered off, washed with copious DMF then DCM and dried in 
vacuo to leave the title compound as an off-white solid (2.10 g, functionality 0.85 
mmol/g by uv monitoring147).





heptadiene-5-ol (0.5 g) was taken in DCM (30 ml) along with t- 
butyloxycarbonylhydrazine (0.5 g, 3.8 mmol) and benzenesulphonic acid (0.03 g,
0.19 mmol) added. The mixture was heated under reflux overnight and the resin 
filtered off, washed with copious DMF, DCM and ether to leave the title compound 
as a white solid (0.5 g).
Found: N, 2.30; expected for 100% loading 2.52%; vmax(KBr disc): 3410 & 3310 
(NH), 3080-2840 (CH), 1710-1670 (2 x C=O),1600 c n r1 (C=C).
2-Copoly(styrene-l%-divinylbenzene)methoxy-5-heptyliminodibenzo- 
cycloheptadiene (112)
2-Copoly(styrene-1 %-divinylbenzene)methoxydibenzocycloheptadiene-5-one (2.0 g) 
was taken in DCM (40 ml) along with heptylamine (2.4 g, 20.9 mmol), cooled on an 
ice/salt bath and stirred under an atmosphere of dry nitrogen. A solution of 1.0M 
titanium (IV) chloride (3.5 ml, 3,5 mmol) was added and the mixture heated under 
reflux for 2.5 h. The resin was then filtered off, washed copiously with DCM and 
dried in vacuo to yield 2.19 g of pale yellow resin.
Found: N, 0.79%; expected for 100% loading, 0.81%; vmax(KBr disc): 3080-2840 





heptadiene (1.5 g) was taken with lithium borohydride (0.2 g, 9.1 mmol) in THF (40 
ml) and heated under reflux for 1.5 h in an atmosphere of dry nitrogen. The mixture 
was then cooled in an ice/salt bath and methanol (5 ml) then acetone (5 ml) carefully 
added. The resin was then filtered off, washed with copious methanol, water then 
methanol again to give 1.4 g of white solid. 
vmax(KBr disc): 3420 (NH), 3080-2840 (CH), 1600 cm' 1 (C=C).
2-Copoly(styrene-1 %  -divinylbenzene)methoxy-5-(9'-fluorenyl-methoxy- 
carbonylglycyIaminoheptyl)dibenzocycloheptadiene (114)
To Fmoc-Gly-OH (1.7 g, 5.8 mmol) in DCM (5 ml) was added thionyl chloride (7 
ml, 68 mmol). The mixture was heated under reflux for 2 h, then cooled and 
concentrated in vacuo. DCM was added (3 x 15 ml) and the mixture concentrated a 
further three times, then the residue taken up in DCM (15 ml) and the solution added 
to 2-copoly(styrene-l%-divinylbenzene)methoxy-5-heptylaminodibenzocyclohepta- 
diene resin (1.2 g), preswollen in DCM (10 ml) and pyridine (2 ml). The mixture 
was stirred at room temperature under an atmosphere of dry nitrogen for 7 h, then 
the resin filtered off and washed with copious DMF and DCM to yield 1.25 g of pale 
yellow solid (functionality by uv monitoring147, 0.15 mmol/g) 





Resin (113) (0.20 g) was added to Fmoc-Leu-OH (0.20 g, 0.566 mmol) in 0.5M 
solution of DIC in 1:1 dioxane/DMF (0.56 ml). 1 ml of dioxane/DMF (1:1) was 
added and the mixture sonicated overnight, the resin was filtered off and washed 
copooisl;y with DMF, DCM then ether. A UV loading test147 showed 0.11 mmol/g 
incorporation of the amino acid. The resin was sonicated for a further 15 h with a 
frash solution of Fmoc-Leu-OH/DIC then the resin filtered and washed with DMF, 





methoxycarbonyl)aminodibenzocycloheptadiene resin (1.0 g, 0.29 mmol/g; 0.29 
mmol) was sonicated in 20% piperidine/DMF for 15 min then the resin was filtered 
off and washed copiously with DMF then DCM. A solution of triphosgene (0.086 g,
0.29 mmol) and diisopropylethylamine (0.10 ml) in DCM (10 ml) was added to the 
resin and nitrogen bubbled through the solution for 30 min. The resin was filtered off 
and washed with DCM (2 x 10 ml). 9-Fluorenylmethoxycarbonylhydrazine160 (0.22 
g, 0.87 mmol) in DCM (20 ml) was added and nitrogen bubbled through the solution 
for 1.5 h. The resin was filtered off and washed copiously with DMF then DCM. 
Resin functionality by uv monitoring147, 0.29 mmol/g.
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Solid phase peptide synthesis was carried out on polystyrene-1%- 
divinylbenzene resin, functionalised with the appropriate linker, using programmed 
cycles on an Applied Biosystems 430A synthesiser. The programme details are 
summarised below.
(1) Capping using protocol A: acetic anhydride (0.5 M in DMF, 1 ml) + pyridine 
(0.5 M in DMF, 1 ml) diluted to 8 ml with DMF, 2.5 and 3.7 min, with 1:1 DMF 
dioxane wash between; or protocol B: 8 ml 0.5 M acetic anhydride/0.125 M 
diisopropylethylamine/0.2% HOBt, 10 min.
(2) Removal of Na -protection: 20% piperidine /DMF ( 2 x 9  ml; 3+1 min).
(3) Washing: 1:1 DMF/dioxane (6x).
(4) Activation: First coupling, symmetrical anhydride formation (2 equiv. unless 
stated) using DIC, 15 min*
Second coupling, HOBt active ester formation (2 equiv. unless stated) 30 min.
(5) Coupling: activated species transferred to reaction vessel, 30 min.
(6) Washing, 1:1 DMF/dioxane (5x).
^Symmetrical anhydride activation was not used for histidine, asparagine or 
glutamine, HOBt activation being substituted. Glycine was single coupled using 4 
equiv. of symmetrical anhydride.
Unless stated, the following side-chain protecting groups were used: Arg (Pmc); 
Asp, Glu (t-Bu); Glp (Z); His (Bum); Lys (Boc); Ser, Thr Tyr (t-Bu).
4.3 Peptide Synthesis
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The progress of the synthesis was monitored by passing the Fmoc deprotection 
effluent through a UV flow cell (302 nm), allowing a semi-quantitative analysis of 
the deprotection and acylation cycles
Fmoc-Gastrin-Releasing Peptide (2-27), Fmoc-Pro-Leu-Pro-Ala-Gly-Gly-Gly-
Thr-Val-Leu-Thr-Lys-Met-Tyr-Pro-Arg-GIy-Asn-His-Trp-Ala-Val-Gly-His-
Leu-Met-NH2
The peptide was synthesised using resin (108) (0.51 g, 0.49 mmol/g, 0.25 mmol), 
capping protocol A. The coupling time was extended for residues 2, 3, 9, 10 and 11: 
symmetrical anhydride (45 min), HOBt ester (1.5 h). Histidine was coupled as its 
trityl derivative (HOBt activation). After completion of the synthesis the resin was 





A sample of resin-bound Fmoc-Gastrin-releasing peptide (2-27), (0.133 mmol/g,
0.20 g) was taken in 20% piperidine/DMF (25 ml) and sonicated for 30 min. The 
resin was filtered off and washed with DMF then DCM and swollen in dioxane (1 
ml). Tbfmoc-Val-OH (77 mg, 0.133 mmol, 5 equiv) was dissolved in dioxane (3 ml) 
along with DIC (0.021 ml, 0.133 mmol) and HOBt (18 mg, 0.133 mmol) and after 
sonicating for 5 minutes was added to the resin. The mixture was sonicated overnight 
then for a further 2.5 h with a further 5 equiv of Tbfmoc-Val-OH HOBt ester.
A sample of the resin-bound Tbfmoc-peptide (50 mg) was taken in TFA (9.5 
ml)/water (0.5 ml)/EDT (0.2 ml)/EMS (0.2 ml)/thioanisole (0.2 ml)/phenol (0.5 g)
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and stirred in an atmosphere of dry nitrogen for 3 h, after which time the resin was 
filtered off and washed with TFA (2 ml). The filtrate was concentrated in vacuo and 
the crude peptide (26 mg) precipitated with ether and filtered off. 
m/z (FAB): 3281.9 (MH+);
HPLC: (column B, gradient 4) Rt 19.8 min.
Purification of Gastrin-Releasing peptide on PGC
Crude Tbfmoc-gastrin-releasing peptide (50.6 mg) was dissolved in 50% aqueous 
CH3CN/1% TFA (30 ml) and applied to a glass column packed with PGC (50-100
fim, 68 m2/g, 3 g, 1 cm diameter), monitoring the eluent by analytical HPLC 
(column B, gradient 4). The column was then subjected to the following wash 
protocol:
1. 50% aqueous CH3CN/0.5% TFA, (50 ml);
2. 50% aqueous CH3CN, (2 x 50 ml);
3. 50% aqueous CH3CN/1% piperidine, (50 ml);
4. 50% aqueous CH3CN, (20 ml);
5. 50% aqueous CH3CN/0.5% TFA, (50 ml);
6. 60% aqueous CH3CN/0.5% TFA, (50 ml);
7. 70% aqueous CH3CN/0.5% TFA (3 x 50 ml);
The product eluted in washes 5-7 and these were combined and lyophilised to give 
an oily solid which on trituration wtih ether gave a white solid (20 mg).
Amino acid analysis: Thr 2.20, Pro 3.17, Gly 5.32, Ala 2.36, Val 3.06, Met 1.95, 
Leu 3.07, Tyr 0.99, His 2.12, Lys 1.00, Arg 1.06; 
m/z (FAB): 2863.9;
HRMS: 2859.51071. C130H205N38O3 jS2 requires 2859.51068.
HPLC: (column B, gradient 4) Rt 11.6 min.
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Leu-Ile-Phe-Ala-Gly-Resin
Wang resin (0.80 mmol/g, 1.0 g), pre-swollen in DMF (4 ml), was sonicated with 2 
equiv of glycine symmetrical anhydride (formed using DIC) in DMF (5 ml) for 3.5 h 
in the presence of DMAP (10 mg). The resin was filtered and washed with DMF , 
DCM then ether (Fmoc loading test indicated a funtionality of 0.61 mmol/g). A 
sample of this resin (0.42 g, 0.25 mmol) was taken and the peptide assembled using 
standard cycles, capping protocol B. The resin-bound peptide was washed with DMF 
DCM then ether to give 0.51 g of white solid.
General procedure for incorporation of Tbfmoc group onto the N-termini of 
resin-bound peptides
Typically 50 mg of resin-bound peptide is sonicated for 3 h with 3 equivalents of 
either Tbfmoc-Cl or a 2:1 mixture of Tbfmoc-OPfp/Tbfmoc-Cl in DCM (2 ml) in 
the presence of 3 equivalents of diisopropylethylamine. The resin is then filtered off 
and washed copiously with DCM then ether. The Tbfmoc functionality is estimated 
by measuring the UV spectrum of an accurately weighed portion of the resin (1-2 
mg) in 20%piperidine/dioxane:
Tbfmoc functionality = 0.613 x ABSggg nm > m = mass °f resin (mS)
m
Tbfmoc-Hepatitis B surface antigen, PreSl (1-23) avw, Tbfmoc-Met-Gly-Gln-
Asn-Leu-Ser-Thr-Ser-Asn-Pro-Leu-Gly-Phe-Phe-Pro-Asp-His-Gln-Leu-Asp-
Pro-AIa-Phe-OH
A sample of the resin-bound Tbfmoc-peptide (0.3 g, Tbfmoc functionality 0.122 
mmol/g) was stirred in TFA (10 ml)/EDT (0.25 ml), water (0.5 ml)/phenol (0.75 g)
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for 2 h in an atmosphere of dry nitrogen. The resin was filtered off and the filtrate 
concentrated in vacuo, then the crude peptide (0.198 g) precipitated with ether. 
HPLC: (column B, gradient 8) Rt 15.9 min.
Purification of Hepatitis B surface antigen, PreSl (1-23) avw. Met-Gly-Gln-
Asn-Leu-Ser-Thr-Ser-Asn-Pro-Leu-GIy-Phe-Phe-Pro-Asp-His-Gln-Leu-Asp- 
Pro-Ala-Phe-OH on PGC
A solution of the crude Tbfmoc-peptide (9.3 mg) in 70% aqueous CH3CN (10 ml) 
was applied to a glass column packed with PGC (50-100 (im, 68 m2/g, 0.5 g, column
length 5.2 cm), monitoring the eluent by analytical HPLC (column B, gradient 8). 
The column was then eluted with 4 x 10 ml of 70% aqueous CH3CN/1% piperidine,
the fractions combined and acidified with acetic acid. The solution was diluted with 
water (200 ml) and desalted on a HPLC column, eluting the salt with 100% solvent 
A then the peptide with 90% B. The eluent was lyophilised to give the peptide as a 
white fluffy solid (5.9 mg).
Amino acid analysis: Asx 4.10, Thr 1.03, Ser 1.76, Glx 2.19, Pro 3.12, Gly 2.16, Ala
1.05, Met 0.91, Leu 2.88, Phe 3.16, His 0.59; 
m/z (FAB): 2538.2;
HRMS: 2534.18554. C114H 166N29035S requires 2534.18545;
HPLC: (column B, gradient 8) Rt 10.4 min.
Tbfmoc deprotection studies on Tbfmoc-Hepatitis B surface antigen, PreSl (1-
23) avw. Tbfmoc-Met-GIy-Gln-Asn-Leu-Ser-Thr-Ser-Asn-Pro-Leu-Gly-Phe-
Phe-Pro-Asp-His-Gln-Leu-Asp-Pro-Ala-Phe-OH, adsorbed on PGC
A sample of the crude Tbfmoc-peptide (1-1.5 mg) was taken in THF (0.10 ml) and 
diluted to 5 ml with 70% aqueous CH3CN. PGC (50-100 (im, 68 m2/g, 0.12 g) was
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added to the solution and the quantitaive adsorption of the Tbfmoc-peptide
confirmed by the UV spectrum of the supernatant between 350-400 nm. The
supernatant was discarded and the PGC suspended in 5 ml of the deprotection
mixture. 0.2 ml aliquots of the supernatant were taken at 1, 2, 5, 10, 15, 30, 60. 120
and 180 min intervals as appropriate, the samples neutralised with acetic acid and the
release of the Tbfmoc-deprotected peptide monitored by analytical HPLC (column
B, gradient 8). Tbfmoc deprotection was judged to be complete when no further 
increase in the peptide peak height (Rt 10.4 min) was observed.






Resin bound Tbfmoc-peptide (0.10 g, Tbfmoc functionality 0.014 mmol/g, 62% 
incorporation) was stirred in TFA (5ml)/EDT (0.38 ml)/Phenol (0.38 g)/thioanisole 
(0.25 ml)/water (0.25 ml) for 3 h in an atmosphere of dry nitrogen. The resin was 
filtered off, washed with a little TFA and the filtrate concentrated in vacuo and the 
crude Tbfmoc-peptide (0.052 g ) precipitated with ether.
Purification of MeCP2 Methylated DNA Binding Domain on PGC
Crude Tbfmoc-peptide (21.2 mg) was dissolved in 50% acetic acid and diluted to 5 
ml with 50% aqueous isopropanol. The solution was filtered and PGC (HPLC grade, 
5 pm, 60 mg) added. Adsorption of the Tbfmoc-peptide was monitored by analytical
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HPLC (column B, gradient 4). After centrifugation, the solvent was decanted off and 
the PGC subjected to the following wash protocol:
1. 2.5% acetic acid/50% aqueous isopropanol (5 ml);
2. 50% aqueous isopropanol (5 ml);
3. 50% aqueous isopropanol/10% piperidine (2 ml), 10 min;
4. 50% aqueous isopropanol (2 ml);
5. 50% aqueous isopropanol/10% piperidine (2 ml);
6. 50% aqueous isopropanol (2 ml);
Washes 3-6 were combined and the solvent removed in vacuo. The residue was
dissolved in aqueous acetic acid, filtered to remove fine carbon particulate and a
final purification effected by semi-preparative HPLC (cloumn G, gradient 10). The
eluent was lyophilised to give the product as a white fluffy solid (1.0 mg)
Amino acid analysis: Asx 10.47, Thr 5.06, Ser 5.67, Glx 6.39, Pro 5.15, Gly 6.53,
Ala 4.74, Val 4.51, Met 0.80, lie 3.38, Tyr 3.41, Phe 3.61, Lys 6.97, Arg 7.2;
m/z (Laser desorption): 9726 (required 9627).






The resin-bound Tbfmoc peptide (Tbfmoc-functionality, 0.026 mmol/g, 85%
incorporation, 88 mg) was taken in TFA (4 ml)/EMS (0.25 ml)/thioanisole (0.25
ml)/anisole (0.25 ml)/water (0.25 ml) and stirred for 4h in an atmosphere of dry
nitrogen. The resin was filtered off, washed with a little TFA and concentrated in
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vacuo and the crude Tbfmoc-peptide precipitated with ether. The solid was dissolved 
in aqueous acetic acid and lyophilised to give a white solid (42.2 mg).
Purification of Ubiquitin Y59F
Crude Tbfmoc-Ubiquitin Y59F (30 mg) was dissolved in 30% acetic acid and passed 
down a sephadex G-50 column (dimensions 100x2.5 cm), combining the fluorescent 
fractions. After lyophilisation this material was subjected to semi-preparative HPLC 
(wavelength 364 nm, column D, gradient 7), when two main fractions were isolated, 
Tbfmoc-Fl (3.9 mg), Rt 14.8 min (column C, gradient 4), and Tbfmoc-F2 (3.8 mg), 
Rt 16.6 (column C, gradient 4), after lyophilisation. The fractions were dissolved in 
10% aqueous CH3CN (2 ml) and piperidine (0.020 ml) added. After 5 min the 
solutions were acidified with acetic acid (0.20 ml) and purified by semi-preparative 
HPLC (column D, gradient 9), giving FI (0.8 mg) and F2 (0.5 mg).
Amino acid analysis FI: Asx 8.47, Thr 7.49, Ser 3.09, Glx 16.3, Pro, 2.80, Gly 6.11, 
Ala 2.03, Val 3.86, Met 0.69, lie 6.65, Leu 9.36, Phe 3.26, His 1.16, Lys 8.03, Arg 
4.32;
m/z (laser desorption): 8564;
HPLC: (column C, gradient 4) Rt 11.0 min
Amino acid analysis: Asx 8.21, Thr 7.35, Ser 3.15, Glx 16.08, Pro 2.98, Gly 6.18, 
Ala 2.19, Val 3.91, Met 0.62, lie 6.53, Leu 9.19, Phe 3.31, His 1.05, Lys 7.86, Arg 
4.14;
m/z (laser desorption): 8552;
HPLC: (column C, gradient 4) Rt 11.8 min.
Bombesin, Glp-GIn-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2
Bombesin was prepared twice using (a) resin (92) (0.88 g, 0.57 mmol, 0.5 mmol)and 
(b) resin (108) (0.51 g, 0.49 mmol/g, 0.25 mmol), capping protocol A.
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(a) A portion of the resin-bound peptide (0.5 g of total 1.47 g) was stirred with TFA 
(24 ml)/EDT (0.5 ml)/EMS (0.5 ml)/water (1.25 ml)/anisole (0.5 ml)/thioanisole 
(0.5 ml)/phenol (0.5 g) for 3 h in an atmosphere of dry nitrogen. The resin was 
filtered off and the filtrate concentrated in vacuo. The crude peptide was precipitated 
with ether to yield a white solid (0.204 g). A sample of this material (0.05 g) was 
purified by semi-preparative HPLC on column G, gradient 2 to give the product as a 
white fluffy solid after lyophilisation (0.02 g, 29%).
Amino acid analysis: Asp 1.00, Glu 3.27, Gly 2.00, Ala 0.99, Val 0.95, Met 0.97, 
Leu 1.89, His 0.98, Arg 0.93, Trp 1.02; 
m/z (FAB): 1619.9 (MH+), 965.7, 809.9;
HRMS: 1619.82282. C71Hn iN240 18S requires 1619.82283;
HPLC: (Column A, gradient 1) Rt 21.5 min.
(b) A sample of the dried resin-bound peptide (0.5 g of 1.02 g) was treated as in (a) 
above to give 0.193 g of crude peptide, a portion of which (29.6 mg) was purified by 
semi-preparative HPLC (column G, gradient 3) to give 6.5 mg of the title compound. 
Amino acid analysis: Asp 0.81, Glu 3.29, Gly 2.17, Ala 1.04, Val 1.10, Met 0.87, 
Leu 1.84, His 0.96, Arg 0.90, Trp 1.29;
m/z (FAB): 1619.1 (MH+);
HRMS: 1619.82282. C71Hm N240 18S requires 1619.82283;
HPLC: (Column B, gradient 4) Rt 8.5 min.
Leu-Ile-Phe-Ala-Gly-NH-(CH2)6CH3
The peptide was prepared using resin (114) (1.0 g, 0.15 mmol/g, 0.15 mmol) using 
single symmetrical anhydride coupling (6.7 equiv), capping protocol A.
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A sample of the resin-bound peptide (0.5 g of total 0.95 g) was stirred in TFA (25 
ml)/water (1.25 ml)/anisole (1.25 ml) for 1 h under an atmosphere of dry nitrogen. 
The resin was filterd off and and the filtrate concentrated in vacuo. The product was 
precipitated with water/petroleum ether (40-60) to give the peptide as an off-white 
solid (0.035 g).
Amino acid analysis; Gly 1.07, Ala 1.02, lie 0.94, Leu 0.98, Phe, 0.99; 
m/z (FAB): 617 (MH+), 428, 322;
HRMS: 617.43906. C33H57N605 requires 617.43902.
HPLC: (column A, gradient 5) Rt 23.6 min.
L eu-enkephalin, N-heptylam ide, T y r-G Iy -G ly -P h e-L eu -iC H ^ C t^
This peptide was prepared using resin (116) (0.15 mmol/g, 1.0 g, 0.15 mmol), using 
double couple cycles with 3.33 equiv of activated species, capping protocol A.
The resin-bound peptide was washed with DMF then DCM and dried in vacuo to 
give 1.03 g. A sample of the resin (0.5 g) was taken in TFA (10 ml)/water (0.5 
ml)/anisole (0.5 ml) and the mixture stirred in an atmosphere of dry nitrogen for 1 h. 
The resin was filtered off and the peptide precipitated with ether, filtered off, 
dissolved in aqueous acetic acid and lyophilised to give 31.6 mg of crude peptide. A 
small portion of this (6.0 mg) was dissolved in 50% acetic acid and purified by semi­
preparative HPLC (column G, gradient 6) to give 5.0 mg (55%) of pure peptide after 
lyophilisation.
Amino acid analysis: Gly 1.99, Leu 1.02, Tyr 0.93, Phe 1.06; 
m/z (FAB: 654 (MH+);
HRMS: 653.40261. C35H53N60 6 requires 653.40263.
HPLC: (column B, gradient 4) Rt 15.1 min.
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Leu-IIe-Phe-Ala-azaG Iy-NH 2
This peptide was prepared using resin (119) (0.29 mmol/g, 0.86g, 0.25 mmol) using 
capping protocol B.
The resin-bound peptide was awashed with DMF then DCM and dried in vacuo. A 
portion of the resin (0.5 g) was taken in TFA (9.5 ml)/water (0.5 ml) and sonicated 
for 1 h. The resin was filtered off and washed with a little TFA, then the filtrate was 
concentrated in vacuo and the peptide (85 mg) precipitated with ether. A sample of 
the crude peptide (46.8 mg) was dissolved in 5% acetic acid and purified by semi­
preparative HPLC in three portions (column F, gradient 7) to give the title compound 
as a white fluffy solid (16.5 mg, 52%) after lyophilisation.
Amino acid analysis: Ala 1.04, He 0.93, Leu 0.99, Phe 1.03; 
m/z (FAB): 520 (MH+);
HRMS: 520.32474. C25H42N70 5 requires 520.32474..
HPLC: (column A, gradient 4) Rt 11.4 min.
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APPENDIX
Microanalysis Results for 8Z>H-Tetrabenzo[a,c,g,*]fluorene (61) *69
Instrument: Perkin-Elmer 2400 elemental analyser
Mass (me) Operating Conditions % c % H
1.323 Normal running conditions0 93.3 4.91
1.474 Extended combustion, 40 sec. 92.8 4.50
1.376 Extended combustion, 60 sec. 92.4 4.14
1.377 Oxygen fill +2 sec. 
Oxygen boost +1 sec.
93.4 4.86
1.343 Oxygen fill +2 sec. 
Oxygen boost +1 sec., +V2 O5
93.7 4.96
1.801 Oxygen fill +3 sec. 
Oxygen boost +2 sec., +V2 O5
94.2 5.07
1.642 Oxygen fill +5 sec. 
Oxygen boost +2 sec., +V2 O5
93.5 5.12
1.374 Oxygen fill +3 sec. 
Oxygen boost +2 sec., +V2 O5
94.0 5.08
aAs recommended by the manufacturer
(Molecular formula C 29H18 requires C, 95.1%; H, 4.92%)
Courses attended
Organic research seminars (various speakers)
Topics in Organic Chemistry (various speakers, University of Edinburgh)
NMR Specroscopy (Dr I.H. Sadler and Dr J. Parkinson)
Medicinal Chemistry (Professor R. Baker and colleagues, Merck Sharp and Dohme) 
Mass Spectrometry (various speakers, ICI)
Chemical Development in the Phamaceutical Industry (various speakers, SmithKline 
Beecham)
Discovery and Development of Zoladex (ICI, various speakers)
Hirst Memorial Lecture, Unversity of St Andrews (Professor S.J. Benkovic, 
Pennsylvania State University)
Symposium on Protein Engineering, Royal Society of Edinburgh (various speakers)
